US11958886B2 - IL-1RA cDNAs - Google Patents
IL-1RA cDNAs Download PDFInfo
- Publication number
- US11958886B2 US11958886B2 US16/467,141 US201716467141A US11958886B2 US 11958886 B2 US11958886 B2 US 11958886B2 US 201716467141 A US201716467141 A US 201716467141A US 11958886 B2 US11958886 B2 US 11958886B2
- Authority
- US
- United States
- Prior art keywords
- codon
- joint
- eqil
- gene
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 108020004635 Complementary DNA Proteins 0.000 title description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 128
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 64
- 230000014509 gene expression Effects 0.000 claims description 99
- 241000283073 Equus caballus Species 0.000 claims description 80
- 239000002245 particle Substances 0.000 claims description 53
- 241000702421 Dependoparvovirus Species 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 30
- 125000003729 nucleotide group Chemical group 0.000 claims description 30
- 230000003612 virological effect Effects 0.000 claims description 17
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 10
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 9
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 9
- 238000011282 treatment Methods 0.000 abstract description 39
- 239000000203 mixture Substances 0.000 abstract description 18
- 230000003412 degenerative effect Effects 0.000 abstract description 14
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 abstract 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 abstract 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 163
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 161
- 210000001503 joint Anatomy 0.000 description 86
- 210000004027 cell Anatomy 0.000 description 71
- 239000013598 vector Substances 0.000 description 56
- 241001465754 Metazoa Species 0.000 description 53
- 239000005090 green fluorescent protein Substances 0.000 description 53
- 241000283086 Equidae Species 0.000 description 52
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 52
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 52
- 210000001519 tissue Anatomy 0.000 description 50
- 210000001179 synovial fluid Anatomy 0.000 description 41
- 238000002347 injection Methods 0.000 description 38
- 239000007924 injection Substances 0.000 description 38
- 230000007170 pathology Effects 0.000 description 38
- 239000013612 plasmid Substances 0.000 description 34
- 210000000845 cartilage Anatomy 0.000 description 30
- 108700019146 Transgenes Proteins 0.000 description 28
- 210000003797 carpal joint Anatomy 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- 208000030175 lameness Diseases 0.000 description 28
- 150000007523 nucleic acids Chemical class 0.000 description 27
- 108020004707 nucleic acids Proteins 0.000 description 26
- 102000039446 nucleic acids Human genes 0.000 description 26
- 239000002299 complementary DNA Substances 0.000 description 25
- 241000701022 Cytomegalovirus Species 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 230000003902 lesion Effects 0.000 description 20
- 230000008439 repair process Effects 0.000 description 18
- 210000001258 synovial membrane Anatomy 0.000 description 18
- 208000014674 injury Diseases 0.000 description 17
- 239000013607 AAV vector Substances 0.000 description 16
- 230000014616 translation Effects 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- 230000008901 benefit Effects 0.000 description 15
- 210000000988 bone and bone Anatomy 0.000 description 15
- 210000001612 chondrocyte Anatomy 0.000 description 15
- 230000037231 joint health Effects 0.000 description 15
- 239000012634 fragment Substances 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 238000013519 translation Methods 0.000 description 14
- 238000011144 upstream manufacturing Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000003623 enhancer Substances 0.000 description 13
- 230000003628 erosive effect Effects 0.000 description 13
- 210000003194 forelimb Anatomy 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 210000000234 capsid Anatomy 0.000 description 12
- 238000001476 gene delivery Methods 0.000 description 12
- 238000002595 magnetic resonance imaging Methods 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 102000000589 Interleukin-1 Human genes 0.000 description 10
- 108010002352 Interleukin-1 Proteins 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000002459 sustained effect Effects 0.000 description 10
- 238000012549 training Methods 0.000 description 10
- 230000009261 transgenic effect Effects 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000013609 scAAV vector Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 210000001188 articular cartilage Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 201000004595 synovitis Diseases 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000002085 persistent effect Effects 0.000 description 7
- 101150044789 Cap gene Proteins 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000008558 Osteophyte Diseases 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 210000005222 synovial tissue Anatomy 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 208000010392 Bone Fractures Diseases 0.000 description 5
- 206010017076 Fracture Diseases 0.000 description 5
- 206010023215 Joint effusion Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000000281 joint capsule Anatomy 0.000 description 5
- 210000005067 joint tissue Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 201000008968 osteosarcoma Diseases 0.000 description 5
- 101150066583 rep gene Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 210000003010 carpal bone Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000002962 histologic effect Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000008073 immune recognition Effects 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 3
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 3
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 206010060820 Joint injury Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000002456 anti-arthritic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000000386 athletic effect Effects 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000002849 chondrocalcinosis Diseases 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012470 diluted sample Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 201000010934 exostosis Diseases 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000012250 transgenic expression Methods 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003011 chondroprotective effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 102000046824 human IL1RN Human genes 0.000 description 2
- 238000010832 independent-sample T-test Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004072 osteoblast differentiation Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000005065 subchondral bone plate Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 1
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 1
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006262 Breast inflammation Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000003274 CINCA syndrome Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012978 Diffuse vasculitis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150066038 E4 gene Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000025127 Erdheim-Chester disease Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000011666 Ill-defined disease Diseases 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010057605 Interferon gamma receptor deficiency Diseases 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010073853 Osteochondral fracture Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 201000004854 SAPHO syndrome Diseases 0.000 description 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067774 Tumour necrosis factor receptor-associated periodic syndrome Diseases 0.000 description 1
- 206010061399 Urticaria thermal Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000001564 haversian system Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002075 inversion recovery Methods 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000001503 one-tailed test Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000012802 recumbency Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- Osteoarthritis is a degenerative, debilitating condition of weight bearing joints.
- the pathology of OA is marked by the gradual, persistent erosion of the articular cartilage, development of osteophytes at the joint margins, sclerotic growth of subchondral bone, synovitis and in many cases synovitis and joint effusion.
- OA is incurable, difficult to manage, and frequently advances to disabling joint failure.
- osteoarthritis is not only a problem for older individuals, but also younger horses.
- interleukin-1 serves as an intra-articular mediator of cartilage loss, pain and inflammation in large weight-bearing joint conditions, such as osteoarthritis (OA).
- IL-1Ra IL-1 receptor antagonist
- the present disclosure relates, at least in part, to the development of a codon-modified genes encoding equine IL-1Ra (eqIL-1Ra) and human IL-1Ra (hIL-1Ra) and the finding that intra-articular delivery of the codon-modified eqIL-1Ra encoding gene raises the steady state levels of eqIL-1Ra in synovial fluid significantly, e.g., more than 100-fold over background for a period of at least 6 months in equine subjects, and leads to reduced lameness, joint effusion and synovitis in an equine OA model.
- eqIL-1Ra equine IL-1Ra
- hIL-1Ra human IL-1Ra
- the codon-modified eqIL-1Ra encoding gene provides higher levels of expression of eqIL-1Ra compared to the native or endogenous gene, without any change in the amino acid sequence of the eqIL-1Ra protein.
- IL-1Ra expression using codon-modified human IL-1Ra cDNA exceeded that from the native human IL-1Ra sequence by approximately 2-4 fold.
- This disclosure also relates to the finding that in striking contrast to healthy joints, transgene expression after treatment is much higher in diseased synovium, particularly so in regions with inflammation and synovitis, compared to normal or undiseased tissue. This phenomenon results in animals with the worst overall pathology producing the highest levels of IL-1Ra.
- the biosynthetic machinery of the modified cells is directed to overproduce and continuously secrete transgenic IL-1Ra protein into the synovial fluid and surrounding tissue.
- the diseased joint becomes an endogenous site of sustained, elevated IL-1Ra production, eliminating the need for repeated application of the protein, while providing the greatest concentration of the therapeutic specifically at the site of disease.
- the present disclosure provides a recombinant nucleic acid comprising a codon-modified gene encoding IL-1Ra.
- the IL-1Ra is equine.
- the IL-1Ra is human.
- the sequence of the codon-modified gene encoding equine IL-1Ra is of SEQ ID NO: 2.
- the sequence of the codon-modified gene encoding human IL-1Ra is of SEQ ID NO: 10.
- a recombinant nucleic acid comprising a codon-modified gene encoding eqIL-1Ra or human IL-1Ra further comprises a Kozak sequence immediately upstream of the translation start site of the codon-modified gene.
- the Kozak sequence and eq-IL-1Ra encoding gene is of sequence SEQ ID NO: 3.
- the Kozak sequence and human IL-1Ra encoding gene is of sequence SEQ ID NO: 11.
- the Kozak sequences further improve the expression level of human IL-1Ra (hIL-1Ra) or eqIL-1Ra in joints (e.g., in human joints or equine joints respectively).
- a recombinant nucleic acid comprising a codon-modified eqIL-1Ra or hIL-1Ra gene further comprises a promoter upstream of the codon-modified gene encoding eqIL-1Ra or hIL-1Ra.
- a promoter is a cytomegalovirus (CMV) immediate early promoter/enhancer.
- CMV immediate early promoter/enhancer is of sequence SEQ ID NO: 4.
- adeno-associated virus comprising any one of the nucleic acids disclosed herein.
- the rAAV particle is self-complementary (i.e., a scAAV particle).
- the rAAV particle is of serotype 2.5. In some embodiments, the rAAV particle is of serotype 2. In some embodiments, a rAAV particle comprising a codon-modified eqIL-1Ra is AAV2.5. In some embodiments, a rAAV particle comprising a codon-modified hIL-1Ra is AAV2. In some embodiments, a rAAV particle comprising a codon-modified eqIL-1Ra is AAV2. In some embodiments, a rAAV particle comprising a codon-modified hIL-1Ra is AAV2.5.
- a method of treating a degenerative condition of large weight-bearing joints comprises administering to a subject in need thereof any one of the rAAV particles disclosed herein.
- a method of treating a degenerative condition of large weight-bearing joints comprises administering to a subject in need thereof an therapeutically effective amount of any one of the rAAV particles disclosed herein.
- a degenerative condition of large weight-bearing joints is osteoarthritis.
- the subject is equine.
- the subject is human.
- any one of the rAAV particles disclosed herein is administered to a subject by intra-articular injection.
- an equine subject is administered any one of the rAAV particles disclosed herein that comprise codon-modified equine IL-1Ra.
- a human subject is administered any one of the rAAV particles disclosed herein that comprise codon-modified human IL-1Ra.
- FIG. 1 shows sequence of the codon modified equine IL-1Ra cDNA.
- the sequence of the native equine IL-1Ra cDNA is shown on top (SEQ ID NO: 1), and the modified sequence at the bottom (SEQ ID NO: 2).
- the bases are numbered starting from the ATG of the translation initiation site to the translation termination codon.
- the nucleotide substitutions used for modification are indicated by colons.
- the sequence at the bottom indicates the Kozak consensus sequence (17) inserted immediately upstream from the translation start site.
- the modified sequence, including the Kozak consensus sequence is SEQ ID NO: 3.
- FIGS. 2 A- 2 D show the expression of the eqIL-1Ra transgene in vitro and in vivo.
- FIG. 1 A shows eqIL-1Ra in conditioned media at 48 hours following transfection of equine synovial fibroblasts with the Hpa-trs-sk scAAV vector plasmid containing the coding sequences for GFP, native eqIL-1Ra, codon-modified eqIL-1Ra (
- FIG. 2 C shows the anatomic locations of the intercarpal (IC) and metacarpophalangeal (MCP) joints on the equine forelimbs (arrowheads) (right).
- IC intercarpal
- MCP metacarpophalangeal
- FIGS. 3 A- 3 O show the locations and phenotypes of cells transduced by scAAV.GFP following intra-articular injection into healthy and OA joints.
- the intercarpal (IC) joints of 3 healthy horses and 3 with late stage naturally-occurring OA were injected with 5 ⁇ 10 12 vg of scAAV.GFP. Two weeks later, the joint tissues were collected and analyzed for fluorescence.
- FIGS. 3 C- 3 D show scAAV.GFP expression in the villous synovium of a healthy joint.
- FIGS. 3 E- 3 F show GFP expression across the synovial surface of an OA joint.
- FIGS. 3 C and 3 E are from freshly harvested tissues at 10 ⁇ ;
- FIGS. 3 D- 3 F are cross sections in paraffin at 20 ⁇ .
- FIGS. 3 G- 3 H show scAAV.GFP expression in fresh cartilage shaved from a healthy joint.
- FIG. 3 I shows GFP activity in healthy cartilage shaving following 48 hours in explant culture.
- FIGS. 3 J- 3 K show GFP activity in fresh cartilage shaved from an OA joint.
- FIG. 3 L shows GFP activity in OA cartilage from region with visible erosion.
- FIG. 3 M shows GFP expression in cartilage clusters from an OA joint (paraffin section).
- FIG. 3 N shows GFP activity in freshly harvested osteophyte tissue (10 ⁇ ).
- FIG. 3 O shows representative GFP expression in fresh synovial tissue harvested from an antebrachiocarpal joint, immediately proximal to an intercarpal joint receiving scAAV.GFP.
- the images shown are a composite from the 6 animals in both groups. A wide range of exposure times was used to capture the varying fluorescence intensities at different magnifications in the fresh tissue samples of variable thickness and composition. The contrast and brightness of individual panels were adjusted linearly for uniformity of appearance and to reflect fluorescence intensities viewed by direct microscopy.
- FIGS. 4 A- 4 H show GFP expression in equine OA tissues following intra-articular gene delivery with scAAV. Additional fields of interest from results described in FIG. 2 .
- the intercarpal joints of 3 horses with naturally-occurring late-stage OA were injected with 5 ⁇ 10 12 vg of scAAV.GFP, and two weeks later the joint tissues were collected and analyzed for fluorescence. Shown is GFP expression in tissues with pathologic changes characteristic of established OA.
- FIGS. 4 A and 4 B show GFP expression in inflamed synovial tissue by direct fluorescence microscopy of freshly harvested tissues.
- FIG. 4 A is 5 ⁇ and FIG. 4 B is 20 ⁇ .
- FIGS. 4 C and 4 D show GFP activity in OA cartilage from regions with visible erosion. Both are at 5 ⁇ magnification.
- FIGS. 4 E- 4 G show GFP activity in chondrocyte clusters.
- FIG. 4 E shows direct fluorescence in fresh shavings (40 ⁇ ).
- FIGS. 4 F and 4 G are from paraffin sections (20 ⁇ and 40 ⁇ , respectively).
- FIG. 4 G shows GFP expression in fresh osteophyte tissue (20 ⁇ ).
- FIGS. 5 A- 5 G show intra-articular scAAV.eqIL-1Ra gene delivery and expression in an equine OCF model of OA.
- FIG. 5 A is a schematic representation of the Osteochondral Fragment (OCF) efficacy study. A total of 20 horses were divided equally into two groups. Following surgical generation of an osteochondral lesion in the radial carpal bone, the animals in the Treated group received an injection of 5 ⁇ 10 12 vg of scAAV.eqIL-1Ra into the joint space; Control animals received an equal volume of saline. Synovial fluids from both intercarpal joints, peripheral blood, and urine were collected on alternate weeks (*).
- OCF Osteochondral Fragment
- FIG. 5 C is a graph depicting the synovial fluid eqIL-1Ra in the OCF joint of each individual in the Treated group. Each line reflects a different animal.
- FIG. 5 E shows the mean eqIL-1Ra in serum from peripheral blood for 9 of 10 animals in both the Treated and Control groups.
- FIG. 5 F shows the eqIL-1Ra in blood serum from the remaining horses in both the Treated and Control groups, which were >25 ⁇ greater than the other 18 animals in the study prior to treatment.
- FIGS. 6 A- 6 B show changes in joint lameness and synovial fluid PGE 2 levels following treatment with scAAV.eqIL-1Ra.
- FIG. 6 A shows the relative change in mean visual lameness scores between Treated and Control groups during athletic training (left). Relative change in forelimb lameness (vector sum) from the Lameness Locator® inertial sensor motion analysis system (right). For both, mean lameness scores at week 1 were assigned a value of 1.
- FIG. 6 B shows the mean PGE 2 levels in synovial fluid of OCF joints of both the Treated and Control groups. Error bars represent ⁇ SEM; *P ⁇ 0.05.
- FIGS. 7 A- 7 B show an evaluation of MR images for changes in tissue pathology in OCF joints treated with scAAV.eqIL-1Ra.
- Both intercarpal joints of all horses were scanned by MR imaging immediately prior to treatment (Week 0) and at the end of the experimental protocol (Week 12).
- FIG. 7 A shows representative images from axial and sagittal scans (PD and PD-FS, respectively) of OCF joints from one horse in the Treated and Control groups.
- White arrows indicate: CE-capsular effusion; ME—marrow edema; OCF— osteochondral fragment; SE—synovial effusion.
- Black arrow in Week 12 sagittal scan for the control joint indicates hyperintense signal and incomplete OCF repair.
- FIG. 7 B shows covariate analyses of the major joint pathologies associated with the OCF model in Treated and Control groups at endpoint (Week 12) using the pretreatment scores (Week 0) as baselines (left).
- Total MRI scores for the OCF joints were calculated from the values of the individual MRI pathologies (right, cross-hatch).
- Total MRI scores from Sham operated joints represent baseline pathology levels in opposing intercarpal joints. Error bars represent ⁇ SEM; *P ⁇ 0.05.
- FIGS. 8 A- 8 D show an evaluation of OCF joint arthroscopies and histologic sections for changes in tissue pathology associated with scAAV.eqIL-1Ra treatment.
- Both intercarpal joints of the horses in the Treated and Control groups were examined arthroscopically following generation of the osteochondral lesion (Week ⁇ 2) and at endpoint (Week 12). Images were scored for OCF size and local cartilage damage, synovitis, cartilage damage throughout the joint (overall) and ligament inflammation. At endpoint, the osteochondral fragment and regional synovial tissue were removed, sectioned and stained with H&E or toluidine blue and graded.
- FIG. 8 A- 8 D show an evaluation of OCF joint arthroscopies and histologic sections for changes in tissue pathology associated with scAAV.eqIL-1Ra treatment.
- FIG. 8 A shows covariate analyses of arthroscopic assessments of the major joint pathologies associated with the OCF model in Treated and Control groups at Week 12 using the scores at Week ⁇ 2 as baseline (left).
- Total arthroscopy scores for the OCF joints were calculated from the values of the individual pathologies (right, cross-hatched bars).
- Total scores from Sham operated opposing intercarpal joints represent baseline pathology in uninjured joints.
- FIG. 8 B presents representative arthroscopic images of the osteochondral lesions in Treated and Control horses at the time of generation (Week ⁇ 2) and at endpoint (Week 12).
- FIG. 8 C shows the mean histologic scores for individual tissue pathologies in collected OCF tissues (left). Total histologic scores calculated from the individual tissue scores (right).
- FIG. 8 D shows representative microscopic images of bone repair tissue in Treated and Controls. Error bars represent ⁇ SEM; *P ⁇ 0.05.
- FIGS. 9 A- 9 B show associations between eqIL-1Ra expression and joint pathology.
- FIG. 9 A shows plots of total MRI score in the Treated horses immediately prior to scAAV.eqIL-1Ra injection vs OCF synovial fluid eqIL-1Ra levels at week 2 (left) and mean eqIL-1Ra levels from weeks 2-12 (right).
- the arrow designates the data point from one horse with unusually high eqIL-1Ra expression at week 2 relative to the other 9 animals (see FIG. 5 C ).
- the solid lines show the best fit line plots for the data points of all 10 animals.
- the dashed lines show the best fit line plots calculated without the outlying data point.
- FIG. 9 B is a plot of total MRI scores immediately prior to injection versus total MRI score at endpoint for the OCF joints for each of the horses in the Treated (gray) and Control (black) groups. The solid lines show the best fit line plots for each group. The corresponding line equations and Pearson correlation coefficients are also shown. *P ⁇ 0.05.
- FIG. 10 shows secretion of human IL-1Ra in HEK293 cells transfected with scAAV vector plasmids containing native or codon-modified human IL-1Ra cDNA.
- FIG. 11 shows secretion of human IL-1Ra in human osteosarcoma cells transfected with scAAV vector plasmids containing native and modified human IL-1Ra cDNA. Error bars show the SEM.
- FIG. 13 shows alignment of the sequences of the native human IL-1Ra cDNA (top sequence; SEQ ID NO: 9) and the GeneArt codon modified IL-1Ra sequence (bottom sequence; SEQ ID NO: 10) with consensus Kozak sequence (underlined) immediately upstream of the ATG translation start site at position 1. Differences between the two sequences are indicated by colons. As indicated beneath the sequence alignments, 105 of the 534 nucleotides in the native IL-1Ra cDNA sequence were changed in the modification. The modified sequence, including the Kozak consensus sequence, is SEQ ID NO: 11.
- Il-1Ra is a promising therapeutic for diseases of degenerative condition of large weight-bearing joints such as osteoarthritis (OA) since it is a natural antagonist of IL-1, which is implicated in intra-articular cartilage loss, pain and inflammation.
- OA osteoarthritis
- delivering IL-1Ra to the site of disease, i.e., the joints is challenging.
- Sustaining a therapeutically effective level of IL-1Ra in a diseased joint for a long period of time is even more challenging.
- endogenous IL-1Ra is expressed at low levels.
- exogenous expression of IL-1Ra using the wild-type nucleotide sequence that encodes eqIL-1Ra protein also does not aid in achieving high levels of IL-Ra in joints.
- the inventors of this disclosure developed a codon-modified nucleic acid sequence that encodes eqIL-1Ra that has the same amino acid sequence as wild-type eqIL-1Ra protein, but results in higher exogenous expression levels of IL-1Ra.
- a further modification was made to include a Kozak sequence immediately upstream of the translation start site. Inclusion of this Kozak sequence further improves the level of expression of eqIL-1Ra protein. Delivery of the developed codon-modified IL-1Ra encoding gene to joints was achieved by use of AAV particles as carriers. Surprisingly, it was found that there is a strong correlation between the level of pathology in a joint at the time of injection and downstream IL-1Ra production. Surprisingly, diseased tissue expresses higher levels of eqIL-1Ra by the disclosed treatment method than tissue that is not diseased.
- the inventors also developed codon-modified human IL-1Ra (hIL-1Ra) with and without Kozak leader sequences that result in secretion of IL-1Ra at levels that are approximately 2-4 times higher than that by native hIL-1Ra cDNA.
- hIL-1Ra codon-modified human IL-1Ra
- a recombinant nucleic acid comprising a codon-modified gene encoding equine IL-1Ra (eqIL-1Ra).
- the nucleotide sequence mismatch between an eqIL-1Ra encoding codon-modified gene and the endogenous (or wild-type or native) eqIL-1Ra encoding gene is 10-30% (e.g., 15-25%, 17-23%, 19-21%, 10-15%, 15-20% 20-25% or 25-30%). That is, 10-30% of the nucleotides encoding eqIL-1Ra are codon-modified.
- the eqIL-1Ra encoding codon-modified gene has 20.2% mismatch compared to the wild-type eqIL-1Ra encoding gene.
- SEQ ID NO: 1 provides the nucleotide sequence of wild-type eqIL-1Ra encoding gene.
- SEQ ID NO:2 provides a codon-modified sequence encoding eqIL-1Ra. 108 out of 534 nucleotides of SEQ ID NO: 2 are mismatched compared to SEQ ID NO: 1, which corresponds to a mismatch of 20.2% ( FIG. 1 ).
- transduction of a cell with a codon-modified eqIL-1Ra encoding gene results in eqIL-1Ra protein levels that are 5-200 fold higher (e.g., 5-200, 10-150, 15-120, 20-100, 30-80, 35-60, 40-50 fold higher) compared to when a similar cell is transduced with endogenous (or native or wild-type) eqIL-1Ra encoding gene.
- a wild-type eqIL-1Ra encoding gene is one that is native or endogenous, or found in horses.
- a codon-modified eqIL-1Ra encoding gene is preceded by a Kozak sequence.
- a Kozak sequence immediately precedes the translation start site of a codon-modified eqIL-1Ra encoding gene.
- a Kozak sequence is 1-50 nucleotides upstream from the translation start site of a codon-modified eqIL-1Ra encoding gene.
- a Kozak sequence is GCCACC.
- SEQ ID NO: 3 provides an example of a codon-modified eqIL-1Ra encoding gene that is immediately preceded by a Kozak sequence.
- transduction of a cell with a codon-modified eqIL-1Ra encoding gene with a Kozak sequence results in eqIL-1Ra protein levels that are 5-200 fold higher (e.g., 5-200, 10-150, 15-120, 20-100, 30-80, 35-60, 40-50 fold higher) compared to when a similar cell is transduced with endogenous eqIL-1Ra encoding gene.
- a similar cell is one that has the same genetic make-up and is cultured and treated in the same manner except that one variable effecting the cell is different, e.g., the sequence of the IL-1Ra cDNA that is used to transfect it.
- nucleotide sequence mismatch between an human IL-1Ra encoding codon-modified gene and the endogenous (or wild-type or native) human IL-1Ra encoding gene is 10-30% (e.g., 15-25%, 17-23%, 19-21%, 10-15%, 15-20% 20-25% or 25-30%). That is, 10-30% of the nucleotides encoding human IL-1Ra are codon-modified.
- the human IL-1Ra encoding codon-modified gene has 19.6% mismatch compared to the wild-type human IL-1Ra encoding gene.
- SEQ ID NO: 9 provides the nucleotide sequence of wild-type human IL-1Ra encoding gene.
- SEQ ID NO:10 provides an example of a codon-modified sequence encoding human IL-1Ra. 105 out of 534 nucleotides of SEQ ID NO: 10 are mismatched compared to SEQ ID NO: 9, which corresponds to a mismatch of 19.6% (see FIG. 13 ).
- a codon-modified human IL-1Ra encoding gene is preceded by a Kozak sequence.
- a Kozak sequence immediately precedes the translation start site of a codon-modified human IL-1Ra encoding gene.
- a Kozak sequence is 1-50 nucleotides upstream from the translation start site of a codon-modified human IL-1Ra encoding gene.
- a Kozak sequence is GCCACC.
- SEQ ID NO: 11 provides an example of a codon-modified human IL-1Ra encoding gene that is immediately preceded by a Kozak sequence.
- transduction of a cell with a codon-modified human IL-1Ra encoding gene with a Kozak sequence results in human IL-1Ra protein levels that are 1.1-50 fold higher (e.g., 1.1-3, 1.4-10, 1.5-30, 2-30, 2-50, 2-4, 2.5-5, 3-8, 5-20 or 30-15 fold higher) compared to when a similar cell is transduced with endogenous human IL-1Ra encoding gene.
- a promoter generally, is a region of nucleic acid that initiates transcription of a nucleic acid encoding a product.
- any of a number of promoters may be employed.
- the promoter may be, for example, a constitutive promoter, tissue-specific promoter, inducible promoter, or a synthetic promoter.
- a recombinant nucleic acid as described herein may include one or more constitutive promoters, such as viral promoters or promoters from mammalian genes that are generally active in promoting transcription.
- constitutive viral promoters include the Herpes Simplex virus (HSV), thymidine kinase (TK), Rous Sarcoma Virus (RSV), Simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV), Ad E1A and cytomegalovirus (CMV) immediate early promoter/enhancer.
- Non-limiting examples of other constitutive mammalian promoters include various housekeeping gene promoters, as exemplified by the ⁇ -actin promoter (e.g., chicken ⁇ -actin promoter) and human elongation factor-1 ⁇ (EF-1 ⁇ ) promoter.
- ⁇ -actin promoter e.g., chicken ⁇ -actin promoter
- EF-1 ⁇ human elongation factor-1 ⁇
- a promoter in any one of the recombinant nucleic acids disclosed herein is a disease-controlled promoter.
- a disease-controlled promoter is one which allows expression of Il-1Ra encoded by the codon-modified gene to which the promoter is linked in diseased cells or tissue at levels that are higher than those in undiseased cells or tissue.
- a disease-controlled promoter in any one of the recombinant nucleic acids disclosed herein is a cytomegalovirus (CMV) immediate early promoter/enhancer.
- CMV cytomegalovirus
- inclusion of a CMV immediate early promoter/enhancer results in 1.5 to 200 fold higher (e.g., 1.5-150, 2-120, 5-100, 10-80 or 20-50 fold higher) eqIL-1Ra or hIL-1Ra expression levels in diseased tissue compared to undiseased tissue.
- the diseased and undiseased tissue is in the same joint of a subject.
- the diseased and undiseased tissue are in the same subject but in different joints.
- diseased and undiseased tissue are in different subjects. Sequence of the CMV immediate early promoter/enhancer is known in the art and is discussed by Schmidt et al. (Molecular and Cellular Biol., 1990, 10:4406).
- the sequence of a CMV immediate early promoter/enhancer is SEQ ID NO: 4. In some embodiments, the sequence of a CMV immediate early promoter/enhancer is a portion of SEQ ID NO: 4 such that the portion provides 20-50% (e.g., 20, 30, 40, 50, 60, 70, 80, 90, 95, 99 or 100%) activity of SEQ ID NO: 4.
- a promoter may be located upstream (e.g., 0 bp to ⁇ 100 bp, ⁇ 30 bp, ⁇ 75 bp, or ⁇ 90 bp) from the transcriptional start site of a nucleic acid encoding a product, or a translation start site may be located within a promoter.
- a promoter is located immediately upstream of a Kozak sequence, or up to 90 bp upstream of a Kozak sequence.
- a promoter may have a length of 100-1000 nucleotide base pairs, or 50-2000 nucleotide base pairs.
- rAAV recombinant adeno-associated particles
- AAV has emerged as one of the most favorable vehicle for gene therapy in clinical applications. Its benefits are related to its increased safety, the low immunogenic profile of transduced cells, and its ability to provide prolonged, effective transgene expression in joint tissues. Recent advances in AAV technology, including the development of self-complementary (double-stranded) vectors, and improved methods for high-titer vector production, have further increased its potential for mainstream clinical use.
- the serotype of the rAAV particle used to deliver any one of the nucleic acids disclosed herein to an equine or human joint is serotype 2.
- the serotype of the rAAV particle used to deliver any one of the nucleic acids disclosed herein to an equine or human joint is serotype 2.5 and is self-complementary (scAAV2.5).
- scAAV2.5 is a second generation AAV vector that includes development of both a novel capsid sequence (chimeric) and unique vector genome structure (duplexed).
- the hybrid AAV serotype 2.5 shows the same tissue tropism as serotype 2, but shows reduced reactivity with AAV2 neutralizing antibody.
- the serotype of the rAAV particle used to deliver any one of the nucleic acids disclosed herein to an equine or human joint is serotype 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, any hybrid serotype, or modified or engineered AAV capsid.
- a rAAV particle is self-complimentary, in that it contains a region of the nucleic acid that is complementary to another region of the nucleic acid, initiating the formation of the double-strandedness of the nucleic acid comprised in a particle.
- a high capacity adenovirus vector is used as a vehicle for delivering any one of the eqIL-1Ra or human IL-1Ra encoding transgenes disclosed herein.
- gene delivery vehicles e.g., lentivirus
- lentivirus can also be used as a vehicle for delivering any one of the eqIL-1Ra or human IL-1Ra encoding transgenes disclosed herein.
- Various gene delivery methods are known in the art, see e.g., Nayerossadat et al. (Adv Biomed Res. 2012; 1: 27), which is incorporated herein by reference in its entirety, and can be used as a vehicle for delivering any one of the eqIL-1Ra or human IL-1Ra encoding transgenes disclosed herein.
- Non-limiting methods of producing rAAV particles that comprise nucleic acid comprising codon-modified gene encoding eqIL-1Ra or human IL-1Ra are described herein.
- Other methods are also known in the art and commercially available (see, e.g., Zolotukhin et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167; and U.S. Patent Publication Numbers US20070015238 and US20120322861, which are incorporated herein by reference; Li et al., J. Virol, 2012, v.86(15) and plasmids and kits available from ATCC and Cell Biolabs, Inc.).
- a plasmid comprising a codon-modified eqIL-1Ra or human IL-1Ra encoding gene may be combined with one or more helper plasmids, e.g., that contain a rep gene (e.g., encoding Rep78, Rep68, Rep52 and Rep40) and a cap gene (encoding VP1, VP2, and VP3, including a modified VP2 region as described herein), and transfected into recombinant cells such that the rAAV particle can be packaged and subsequently purified.
- helper plasmids e.g., that contain a rep gene (e.g., encoding Rep78, Rep68, Rep52 and Rep40) and a cap gene (encoding VP1, VP2, and VP3, including a modified VP2 region as described herein), and transfected into recombinant cells such that the rAAV particle can be packaged and subsequently purified.
- packaging is performed in a helper cell or producer cell, such as a mammalian cell or an insect cell.
- mammalian cells include, but are not limited to, HEK293 cells, COS cells, HeLa cells, BHK cells, or CHO cells (see, e.g., ATCC® CRL-1573TM, ATCC® CRL-1651TM, ATCC® CRL-1650TM, ATCC® CCL-2, ATCC® CCL-10TM, or ATCC® CCL-61TM).
- Exemplary insect cells include, but are not limited to Sf9 cells (see, e.g., ATCC® CRL-1711TM).
- the helper cell may comprises rep and/or cap genes that encode the Rep protein and/or Cap proteins for use in a method described herein.
- the packaging is performed in vitro.
- a plasmid comprising an IL-1Ra encoding gene is combined with one or more helper plasmids, e.g., that contain a rep gene of a first serotype and a cap gene of the same serotype or a different serotype, and transfected into helper cells such that the rAAV particle is packaged.
- helper plasmids e.g., that contain a rep gene of a first serotype and a cap gene of the same serotype or a different serotype
- the one or more helper plasmids include a first helper plasmid comprising a rep gene and a cap gene, and a second helper plasmid comprising one or more of the following helper genes: Ela gene, E1b gene, E4 gene, E2a gene, and VA gene.
- helper genes are genes that encode helper proteins Ela, E1b, E4, E2a, and VA.
- the rep gene is a rep gene derived from AAV3, AAV5, or AAV6 and the cap gene is derived from AAV2, AAV3, AAV5, or AAV6 and may include modifications to the gene in order to produce the modified capsid protein described herein.
- the cap gene is modified such that one or more of the proteins VP1, VP2 and VP3 do not get expressed. In some embodiments, the cap gene is modified such that VP2 does not get expressed. Methods for making such modifications are known in the art (Lux et al.
- Helper plasmids, and methods of making such plasmids are known in the art and commercially available (see, e.g., pDF6, pRep, pDM, pDG, pDP1rs, pDP2rs, pDP3rs, pDP4rs, pDP5rs, pDP6rs, pDG (R484E/R585E), and pDP8.ape plasmids from PlasmidFactory, Bielefeld, Germany; other products and services available from Vector Biolabs, Philadelphia, PA; Cellbiolabs, San Diego, CA; Agilent Technologies, Santa Clara, Ca; and Addgene, Cambridge, MA; pxx6; Grimm et al.
- Plasmids that encode wild-type AAV coding regions for specific serotypes are also known and available.
- pSub201 is a plasmid that comprises the coding regions of the wild-type AAV2 genome (Samulski et al. (1987), J Virology, 6:3096-3101).
- helper plasmids are produced or obtained, which comprise rep and cap ORFs for the desired AAV serotype and the adenoviral VA, E2A (DBP), and E4 genes under the transcriptional control of their native promoters.
- the one or more helper plasmids comprise rep genes for a first serotype (e.g., AAV3, AAV5, and AAV6), cap genes (which may or may not be of the first serotype) and optionally one or more of the adenoviral VA, E2A (DBP), and E4 genes under the transcriptional control of their native promoters.
- the one or more helper plasmids comprise cap ORFs (and optionally rep ORFs) for the desired AAV serotype and the adenoviral VA, E2A (DBP), and E4 genes under the transcriptional control of their native promoters.
- the cap ORF may also comprise one or more modifications to produce a modified capsid protein as described herein.
- HEK293 cells available from ATCC® are transfected via CaPO 4 -mediated transfection, lipids or polymeric molecules such as Polyethylenimine (PEI) with the helper plasmid(s) and a plasmid containing a nucleic acid vector described herein.
- PEI Polyethylenimine
- the HEK293 cells are then incubated for at least 60 hours to allow for rAAV particle production.
- the HEK293 cells are transfected via methods described above with AAV-ITR containing any one of the recombinant nucleic acids described herein, a helper plasmid comprising genes encoding Rep and Cap proteins, and co-infected with a helper virus.
- Helper viruses are viruses that allow the replication of AAV. Examples of helper virus are adenovirus and herpesvirus.
- Sf9-based producer stable cell lines are infected with a single recombinant baculovirus containing any one of the recombinant nucleic acids provided herein.
- HEK293 or BHK cell lines are infected with a HSV containing the nucleic acid vector and optionally one or more helper HSVs containing rep and cap ORFs as described herein and the adenoviral VA, E2A (DBP), and E4 genes under the transcriptional control of their native promoters.
- the HEK293, BHK, or Sf9 cells are then incubated for at least 60 hours to allow for rAAV particle production.
- the rAAV particles can then be purified using any method known in the art or described herein, e.g., by iodixanol step gradient, CsCl gradient, chromatography, or polyethylene glycol (PEG) precipitation.
- a pharmaceutical composition comprising any one of the rAAV particles disclosed herein.
- a pharmaceutical composition comprises a pharmaceutically acceptable carrier that aids in the delivery of rAAV particles comprising a nucleic acid encoding eqIL-1Ra or human IL-1Ra to a joint of a subject.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the rAAV particle is administered.
- Pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum oil such as mineral oil, vegetable oil such as peanut oil, soybean oil, and sesame oil, animal oil, or oil of synthetic origin.
- Saline solutions e.g., sterilized, pyrogen-free saline
- aqueous dextrose and glycerol solutions can also be employed as liquid carriers.
- USP grade carriers and excipients are particularly useful for delivery of rAAV particles to mammalian subjects.
- compositions may further optionally comprise a liposome, a lipid, a lipid complex, a microsphere, a microparticle, a nanosphere, or a nanoparticle, or may be otherwise formulated for administration to the cells, tissues, organs, or body of a subject in need thereof.
- Methods for making such compositions are well known and can be found in, for example, Remington: The Science and Practice of Pharmacy, 22nd edition, Pharmaceutical Press, 2012.
- the pharmaceutical forms of the rAAV particle compositions suitable for injectable use include sterile aqueous solutions or dispersions.
- the form is sterile and fluid to the extent that easy syringability exists.
- the form is stable under the conditions of manufacture and storage and is preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the form is sterile.
- the carrier can be a solvent or dispersion medium containing, for example, water, saline, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
- Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the solution may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
- preparations should meet sterility, pyrogenicity, and the general safety and purity standards generally accepted in veterinary sciences.
- compositions may contain at least about 0.1% of the therapeutic agent (e.g., rAAV particle) or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 70% or 80% or more of the weight or volume of the total formulation.
- the amount of therapeutic agent(s) (e.g., rAAV particle) in each therapeutically-useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound.
- a method of treating a degenerative condition of large weight-bearing joints comprising administering intra-articularly to a subject any one of the rAAV particles disclosed herein.
- a subject is mammalian (e.g., a human or a horse). In some embodiments, the subject is equine. In some embodiments, the subject is human.
- a degenerative condition of large weight-bearing joints is caused by acute trauma (e.g., injury or traumatic loading) or chronic erosive disease.
- a degenerative condition of large weight-bearing joints is osteoarthritis (OA). Equine OA is also known as degenerative joint disease (DJD).
- OA in horses can be caused by trauma to the joint from either an acute incident or constant concussive forces. Immobilization and improper shoeing can also lead to OA in horses.
- any one of the rAAV particles or pharmaceutical compositions is administered in joint needing treatment by intra-articular injection.
- the joints most often affected by arthritis and thus in need of treatment in horses include the knee, fetlock, coffin, hock, and pastern (where it is often referred to as “ringbone”).
- the joint needing treatment is a metacarpophalangeal (MCP) or intercarpal (IC) joint.
- MCP metacarpophalangeal
- IC intercarpal
- a recombinant gene e.g., in an rAAV
- a composition may be delivered systemically.
- any one of the rAAV particles described herein can be used to treat any pathologic condition where sustained production of an IL-1 inhibitor would provide benefit.
- a pathologic condition where sustained production of IL-1 inhibitor would provide benefit is gout, pseudo-gout, or the pain and inflammation associated with gout or pseudo gout.
- pathologic conditions where sustained production of IL-1 inhibitor would provide benefit include rheumatoid arthritis, juvenile arthritis, still's disease, polyarthritis, chronic infantile neurological cutaneous and articular syndrome, vasculitis, systemic lupus erythematosus, psoriatic arthropathy, connective tissue disorder, immune reconstitution syndrome, diffuse vasculitis, schnitzler's syndrome, amyloidosis, histiocytosis haematophagic, muckle-wells syndrome, osteoporosis, polychondritis, ocular hypertension, ankylosing spondylitis, erdheim-chester disease, crush injury, sapho syndrome, multiple injuries, cytolytic hepatitis, scleroderma, amyotrophic lateral sclerosis, tumour necrosis factor receptor-associated periodic syndrome, antiinflammatory therapy, autoimmune disorder, ill-defined disorder, bone marrow disorder, psoriasis, immune system disorder
- a method of treating a pathologic condition comprises administering to a subject in need thereof any one of the rAAV particles disclosed herein extra-articularly.
- any one of the rAAV particles described herein is used to treat a persistent inflammatory condition (e.g., an inflammatory condition in connective tissues).
- a persistent inflammatory condition cause lameness (e.g., tendonitis or laminitis).
- lameness e.g., tendonitis or laminitis
- the chronic inflammation that is treated occurs in the liver, gut or respiratory tissues. It is to be understood that any of the conditions stated above may be considered a degenerative condition of large weight-bearing joints.
- compositions described above or elsewhere herein are typically administered to a subject in a therapeutically effective amount, that is, an amount capable of producing a desirable result.
- a therapeutically effective amount of rAAV particles may be an amount of the particles that are capable of transferring a codon-modified eqIL-1Ra or codon-modified hIL-1Ra encoding gene to an equine or human joint, respectively.
- a therapeutically effective amount may be an amount that is capable of treating a disease, e.g., OA.
- dosage for any one subject depends on many factors, including the subject's size, body surface area, age, the particular composition to be administered, the active ingredient(s) in the composition, time and route of administration, general health, and other drugs being administered concurrently. Treatment may be assessed by a clinical practitioner using standard practices in the art or skills and experience gained in the art (e.g., evaluating inflammation in a joint).
- administering means providing a material to a subject in a manner that is pharmacologically useful.
- 110 10 to 1 ⁇ 10 13 viral genomes (vgs) (e.g., 5 ⁇ 10 10 to 5 ⁇ 10 12 vg, 1 ⁇ 10 11 to 1 ⁇ 10 12 vg or 2 ⁇ 10 11 to 9 ⁇ 10 11 vg) are administered at a time into a joint to be treated.
- the volume of pharmaceutical composition or rAAV being injected is 1-20 ml (e.g., 2-15, 5-12 or 5-10 ml).
- rAAV particles comprising codon-modified eqIL-1Ra encoding gene is administered to an equine joint on a regular basis, for example every 3 months, 6 months or every year or 2-5 years. In some embodiments, rAAV particles comprising codon-modified hIL-1Ra encoding gene is administered to a human joint on a regular basis, for example every 3 months, 6 months or every year or 2-5 years.
- rAAV particles comprising codon-modified eqIL-1Ra or hIL-1Ra encoding gene is administered to an equine joint or human joint multiple times (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15 or 20 times), either at regular intervals of time or irregular intervals of time.
- rAAV comprising codon-modified eqIL-1Ra or codon-modified hIL-1Ra encoding gene is administered to a joint only once.
- rAAV comprising codon-modified eqIL-1Ra or codon-modified hIL-1Ra encoding gene is administered to an equine or human joint only if symptoms of disease return or increase. In some embodiments, rAAV comprising codon-modified eqIL-1Ra or codon-modified hIL-1Ra encoding gene is administered to an equine or human joint immediately after a condition (e.g., OA) is diagnosed (e.g., within 1 month or 1 year of diagnosis).
- a condition e.g., OA
- rAAV comprising codon-modified eqIL-1Ra or codon-modified hIL-1Ra encoding gene is administered to an equine or human joint before a degenerative condition is diagnosed, but after the occurrence of an event (e.g., an injury) that could lead to a degenerative condition.
- rAAV comprising codon-modified eqIL-1Ra or codon-modified hIL-1Ra encoding gene is administered to an equine or human joint immediately after (e.g., within a month) the occurrence of a trauma that could lead to a degenerative condition.
- rAAV comprising codon-modified eqIL-1Ra or codon-modified hIL-1Ra encoding gene is administered to an equine or human joint when the first signs of joint disease are observed.
- symptoms of a degenerative condition of large weight-bearing joint include limping or lameness, joint swelling, decreased turnout activity, and stiffness or decreased movement of the joint.
- injection of rAAV comprising codon-modified eqIL-1Ra or codon-modified hIL-1Ra encoding gene into a diseased joint produces a higher level of IL-1Ra production compared to injection of rAAV comprising codon-modified eqIL-1Ra or codon-modified hIL-1Ra encoding gene into an un-diseased or healthy joint.
- the production of IL-1Ra in a diseased joint is 1.1-50 times (e.g., 1.1-2, 2-4, 2-10, 5-10, 5-20, 10-20, 20-30, or 30-50 times) higher compared to an un-diseased or healthy joint.
- Example 1 scAAV-Mediated Gene Delivery of IL-1Ra for the Treatment of Osteoarthritis: Temporal Expression and Biodistribution in an Equine Model
- scAAV can provide sustained expression of eqIL-1Ra in an equine joint, using a codon-modified gene encoding eqIL-1Ra and a Kozak sequence.
- IL-1Ra transgene To minimize immune recognition of the IL-1Ra transgene product and assemble a pharmacokinetic profile of homologous IL-1Ra gene transfer with the AAV vector, DNA sequences encoding the equine orthologue of IL-1Ra were used as a therapeutic reporter.
- the native eqIL-1Ra cDNA was codon-modified and a consensus Kozak sequence was inserted immediately upstream of the translation initiation codon ( FIG. 1 ). In this construct, expression of the transgene is driven by the CMV immediate early promoter/enhancer.
- AAV vectors were packaged in the AAV2.5 capsid at the University of Florida Vector Core or the University of North Carolina Chapel Hill Vector Core by methods previously described.
- the cDNAs encoding GFP and modified eqIL-1Ra were directionally inserted into the Sac II and Not I sites of the expression cassette of the pHpa-trs-SK plasmid, a self-complementary (double-stranded DNA) AAV vector variant engineered from the genome of AAV2.
- expression of the transgene is driven by the CMV immediate early promoter/enhancer.
- AAV vectors were packaged in the AAV2.5 capsid at the University of Florida Vector Core or the University of North Carolina Chapel Hill Vector Core.
- equine IL-1Ra Levels of equine IL-1Ra was assayed using specific ELISA (R&D Systems). Synovial fluid samples from both Treated and Control joints were diluted 1:1 with buffered saline containing hyaluronidase at 50 u/ml, and incubated at 37° C. for 30 minutes prior to measuring protein content. Two-fold serial dilutions in reagent diluent (R&D Systems) synovial fluid samples were generated over a wide range to account for assay variability. Each dilution series was generated in duplicate, and each diluted sample was assayed in triplicate wells. Means were calculated from samples with readouts within the boundaries of the standard curves of the respective assays.
- the intercarpal joints of 3 healthy horses and 3 with late stage naturally-occurring OA were injected with 5 ⁇ 10 12 vg of scAAV.GFP diluted in 5 ml Lactated Ringer's solution.
- the animals were euthanized two weeks later and necropsied. No significant lesions were detected in organs other than the musculoskeletal system.
- Tissues were harvested from the injected intercarpal joint, the adjacent antebrachiocarpal joint, adjacent quadriceps muscle, ipsilateral MCP joint, contralateral intercarpal joint and adjacent quadriceps muscle, the brain, heart, lung, liver and spleen.
- gDNA genomic DNA
- gDNA was extracted from the stored tissue samples using the Qiagen DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer's instructions. gDNA concentrations were determined using a NanoDrop spectrophotometer (Thermo Scientific).
- Quantitative real-time PCR was performed using 100 ng gDNA and an Eppendorf RealPlex PCR machine (Eppendorf). Primers were designed to anneal to sequences in the CMV promoter of the vector expression cassette. The sequences for the forward and reverse primers were 5′-CACGCTGTTTGACCTCCATAGAAGACAC (SEQ ID NO: 5) and 5′-TTCTTTGATTTGCACCACCACCGGATCCG (SEQ ID NO: 6), respectively. For each set of reactions a standard curve was generated using serial dilutions of the pHpa-tr-sk plasmid DNA.
- PCR reactions specific for equine ⁇ -actin forward primer 5′-CCAGCACGATGAAGATCAAG (SEQ ID NO: 7) and reverse primer 5′-GTGGACAATGAGGCCAGAAT (SEQ ID NO: 8)) and without template DNA, were used as positive and negative controls, respectively. All gDNA samples were assayed in triplicate. To test for sample-specific reaction inhibition, aliquots of the gDNA samples were spiked with pHpa-trs-SK vector DNA at 100 copies/ ⁇ g of gDNA. If 40 copies/ ⁇ g or more of the spike-in DNA was detected, the gDNA sample was deemed acceptable.
- Tissue samples from the biodistribution study containing visible GFP activity were fixed in paraformaldehyde, processed for histology and paraffin-embedded. Sections cut at 5 ⁇ m and mounted on charged slides were deparaffinized, and heat-mediated antigen retrieval was performed. The slides were blocked with 10% normal serum, then incubated for 1 hour at room temperature with rabbit anti-GFP antibody at a 1:200 dilution (Abcam), followed by biotinylated secondary antibody (Invitrogen) for 30 minutes at room temperature at a dilution of 1:500. The slides were mounted with DAPI (Vector Laboratories) and viewed with a fluorescent microscope.
- DAPI Vector Laboratories
- the cDNA for the equine IL-1Ra orthologue codon was modified and synthesized both with (SEQ ID NO: 3) and without (SEQ ID NO: 2) a consensus Kozak sequence leader immediately upstream of the translation start site.
- both modified constructs generated a 30-50-fold enhancement of expression over the native sequence in transient transfection assays ( FIG. 2 A ).
- the construct including the Kozak sequence consistently provided the greatest levels of eqIL-1Ra expression, it was selected for viral packaging and testing in vivo.
- the eqIL-1Ra vector construct was packaged in the AAV2.5 capsid, which maintains AAV2 tropism, but shows reduced reactivity with AAV2 neutralizing antibody, prevalent among the human population.
- Infection of equine synovial fibroblast cultures with a range of doses of the AAV2.5 vector resulted in exceptionally high expression of eqIL-1Ra, which exceeded 10 ⁇ g/ml at 10 5 viral genomes (vg)/cell ( FIG. 2 B ).
- eqIL-1Ra production did not exceed background in parallel control cultures infected at 10 5 vg/cell with an AAV2.5 vector containing GFP.
- synovial fluid was aspirated from each of the forelimb joints, and peripheral blood and urine were collected.
- eqIL-1Ra content in the biological fluids was measured using commercially available ELISA kits, and interpreted relative to pre-injection values.
- synovial fluid eqIL-1Ra remained at pre-injection levels ( ⁇ 1 ng/ml) throughout ( FIG. 2 B ).
- dose-related increases in synovial fluid eqIL-1Ra were observed within 2-4 weeks of injection, with mean levels ranging from ⁇ 6 ng/ml at 5 ⁇ 10 10 vg to ⁇ 40 ng/ml at 5 ⁇ 10 12 vg. Peak eqIL-1Ra production occurred at between 4 and 8 weeks post-injection, and was maintained for the remainder of the study ( FIG. 2 B ).
- scAAV.eqIL-1Ra As the 5 ⁇ 10 12 vg dose of scAAV.eqIL-1Ra consistently provided the highest eqIL-1Ra production intra-articulalry and appeared reasonably safe, it was selected for further characterization in vivo.
- an scAAV vector construct containing the coding sequence for GFP was packaged in the AAV2.5 capsid. Then, 5 ⁇ 10 12 vg of scAAV.GFP was injected into one intercarpal joint of 3 healthy horses and 3 horses with advanced, naturally-occurring OA ( FIGS. 3 A- 3 B ). Two weeks later, the horses were euthanized, and tissues were collected from the injected joints and sites throughout the body.
- the OA cartilage showed the most dramatic enhancement in GFP activity, as populations of brightly fluorescent cells were readily apparent in all shavings recovered ( FIGS. 3 J- 3 K ). Shavings harvested near full thickness erosions, often contained focal regions with intense fluorescence ( FIGS. 3 L and 4 C- 4 D ), and frequently contained cells with spindle-shaped morphology, consistent with dedifferentiation to fibrochondrocytes (20). Higher magnification showed that GFP expression was visible in a majority of the resident chondrocyte population, but was particularly prominent in chondrocyte clusters characteristic of OA cartilage ( FIGS. 3 M and 4 E- 4 G ). Pockets of brightly fluorescent cells were also visible along the surfaces of osteophytes recovered from the margins of the OA joints ( FIGS. 3 N and 4 H ).
- the synovium of the antebrachiocarpal joint of the carpus was the only tissue outside the intercarpal joint that contained visible fluorescence. Despite its location immediately proximal to the site of injection ( FIG. 2 C ), only sparse fluorescent cells were seen, and in only a few of the harvested samples ( FIG. 3 O ).
- the genetically modified cells can sustain elevated levels of protein synthesis for over 6 months.
- Articular pathologies such as acute trauma or chronic erosive disease, can increase viral transduction and transgenic expression significantly.
- the vast majority of the vector DNA is retained in the articular tissues, and local overproduction of IL-1Ra is not detected in the circulation.
- it may be predicted that the genetically modified cells can sustain elevated levels of protein synthesis for longer than 6 months (e.g., up to 1 year, up to 2 years, up to 5 years or up to 10 years).
- the use of the equine system has proven particularly informative, allowing the capacity of an AAV vector for gene delivery to be tested on a scale relevant to human treatment, and in the context of naturally occurring OA.
- the ability to serially aspirate synovial fluid enables direct quantitation of intra-articular transgene expression and the generation of meaningful pharmacokinetic profiles.
- the use of outbred animals, their variable responses to osteochondral injury, inherent differences in behavior and healing capacity provide a reasonable simulation of the variability associated with the treatment of humans in a clinical setting.
- GFP reporter Substantially higher expression of the GFP reporter was observed in association with the cellular and morphologic changes in the joint typical of advanced OA.
- chronic inflammatory stimulation frequently induces hyperplasia, angiogenesis, leukocytic infiltration, and fibrotic thickening.
- AAV-mediated GFP expression appeared consistently higher throughout the synovium of OA joints, fluorescence was especially pronounced in regions of synovitis, where the increased cellularity served to heighten the density of target cells receptive to AAV transduction.
- Chondrocytes in healthy cartilage largely exist in a non-distressed, resting state.
- OA OA
- degradation of the cartilage matrix diminishes its protective properties, causing excessive mechanical loading on the local chondrocytes.
- NF- ⁇ B nuclear factor ⁇ B
- MAPK stress-induced mitogen activated protein kinases
- the activated chondrocytes undergo a marked change in phenotype; they become proliferative, secrete high levels of inflammatory cytokines, and release proteolytic enzymes that further degrade the local matrix.
- CMV immediate early promoter is generally considered a high-level constitutive promoter
- transcription from this element is known to be responsive to NF- ⁇ B, and signal transduction from p38 and other stress-activated protein kinases.
- engagement of these pathways is required for activation of CMV immediate early promoter and initiation of viral replication.
- inflammation and cellular stress can significantly increase the expression of transgenes under its control (40, 43-45).
- OA cartilage is enriched with stress-activated chondrocytes, which populate regions of erosion at high density.
- GFP expression was also prominent at sites of chondrocyte proliferation and cluster formation, and along the surfaces of osteophytes, which arise from persistent activation of chondro-osseus progenitors at the transition from cartilage to synovium. Potent activation of GFP expression was also seen in the cartilage shavings from healthy joints following incubation in explant culture. As no additional vector was added to the shavings, this induction had to arise from vector DNA already present in the chondrocytes. Therefore, it must reflect a dramatic increase in metabolic and transcriptional activity in transduced chondrocytes from the stress of harvest and/or change in growth conditions.
- the CMV immediate early promoter at least within the context of OA and the large mammalian joint, appears to be innately disease regulated.
- the regional differences in GFP expression seen in OA cartilage indicate the potential with an AAV vector and an expression cassette driven by the CMV promoter to preferentially direct transgene expression to the areas of articular cartilage under the greatest pathologic stress. This lays the foundation for development of targeted chondroprotective and regenerative strategies.
- IL-1Ra transgene To minimize immune recognition of the IL-1Ra transgene product and assemble a pharmacokinetic profile of homologous IL-1Ra gene transfer with the AAV vector, DNA sequences encoding the equine orthologue of IL-1Ra were used as a therapeutic reporter.
- the native eqIL-1Ra cDNA (57, 58) was codon-modified (16)(GeneArt) and a consensus Kozak sequence (17) was inserted immediately upstream of the translation initiation codon ( FIG. 1 ).
- expression of the transgene is driven by the CMV immediate early promoter/enhancer (30).
- AAV vectors were packaged in the AAV2.5 capsid (18, 19), at the University of Florida Vector Core or the University of North Carolina Chapel Hill Vector Core by methods previously described (7).
- equine IL-1Ra (R&D Systems), PGE 2 (R&D Systems) and equine IL-1 ⁇ (GenWay) were assayed using specific ELISA.
- Synovial fluid samples from both Treated and Control joints were diluted 1:1 with buffered saline containing hyaluronidase at 50 u/ml, and incubated at 37° C. for 30 minutes prior to measuring protein content.
- Two-fold serial dilutions in reagent diluent (R&D Systems) of blood serum and synovial fluid samples were generated over a wide range to account for assay variability. Each dilution series was generated in duplicate, and each diluted sample was assayed in triplicate wells. Means were calculated from samples with readouts within the boundaries of the standard curves of the respective assays.
- mice Twenty thoroughbred horses between 2 and 9 years of age, and of mixed gender were used in this phase of the study. The animals were healthy and free of lameness or radiographic signs of carpal joint disease. Prior to induction of the disease model, the horses were conditioned by treadmill exercise 5 days/week for 3 weeks. For each exercise day, the horses were trotted (4-5 m/sec) for 2 min, galloped ( ⁇ 9 m/sec) for 2 min, and again trotted for 2 min. Prior to further use, the animals were randomly divided into equal Treated and Control groups.
- an arthroscopic examination was performed bilaterally in both intercarpal joints.
- an 8 mm osteochondral lesion was created medially off the radiocarpal bone, using an osteotome aligned perpendicular to the articular surface (14).
- the fragment was allowed to remain attached to the capsular tissues.
- debridement of the parent bone (14) was not performed.
- the contralateral joint in each horse served as a sham operated internal control. All horses were housed in a stall for 7 days post-operatively and received appropriate veterinary care.
- the OCF joint of the horses assigned to the Treated group received an injection of 5 ⁇ 10 12 vg of scAAV.eqIL-1Ra suspended in Lactated Ringer's solution in a total volume of 5 mL.
- Horses in the Control group received 5 mL of Lactated Ringer's solution without virus.
- the horses were returned to the 5 day/week treadmill exercise program above, for 10 weeks.
- the horses were given weekly clinical examinations and lameness assessments.
- a final arthroscopic examination was performed on both intercarpal joints. The fragment was removed, and the lesion in the parent bone was debrided and repaired.
- Forelimb lameness was evaluated weekly during the 10 week, post-operative treadmill training period by both subjective and objective methods. Subjective visual lameness assessments were performed by two qualified evaluators, appropriately blinded, with the horses on the treadmill at a walk and a trot ( ⁇ 4 m/sec) according to guidelines of the American Association of Equine Practitioners.
- the grading system was as follows: 0, lameness not perceptible; 1, lameness is difficult to observe and is not consistently apparent; 2, lameness is difficult to observe at a walk or when trotting in a straight line but consistently apparent under certain circumstances; 3, lameness is consistently observable at a trot under all circumstances; 4, lameness is obvious at a walk; 5, lameness produces minimal weight bearing in motion and/or at rest or a complete inability to move.
- Lameness Locator® For objective gait assessment, an inertial sensor-based motion analysis system (Lameness Locator®; Equinosis) was used, that was designed specifically to detect and evaluate lameness in horses (22, 23). For each weekly session, at least 3 measurements were taken at a ⁇ 4 m/sec trot on a treadmill. Each measurement was calculated from a minimum of 30 uninterrupted strides. Lameness was calculated as a vector sum using the mean maximum head difference (HDmax) and mean minimum head difference (HDmin) between the left and right strides for every stride in each measurement (22, 23). HDmax is the difference in the maximum head height that occurs after right forelimb stance to that which occurs after left forelimb stance.
- HDmax is the difference in the maximum head height that occurs after right forelimb stance to that which occurs after left forelimb stance.
- HDmin is the difference in minimum head height that occurs during right forelimb stance to that which occurs during left forelimb stance.
- VS vector sum
- MR examinations of both carpi were performed using a Toshiba Titan (Japan) 1.5 Tesla high-field unit. Under general anesthesia, the horses were placed in left lateral recumbency with each carpus in partial flexion (15-25 degrees) in a quadrature transmit/receive knee coil (QD Knee).
- the MR coil and sequences were selected and modified to be clinically applicable in live horses (24), and included sagittal and axial proton density (PD), dorsal T2-weighted, axial T2 short-tau inversion recovery (STIR), sagittal proton density with fat suppression (PD-FS), and sagittal spoiled gradient echo with fat suppression (SPGR-FS).
- Total acquisition time was approximately one hour and twenty minutes for all sequences on both limbs.
- the MR scans for each horse were examined by three evaluators blinded to treatment group assignment. Following review of the scans from the 6 MR sequences for each intercarpal joint and time point, scores were assigned for the predominant pathologies associated with the model, including synovial effusion, synovial proliferation, severity of the osteochondral lesion, damage to articular cartilage, marrow edema in the radiocarpal bone, sclerosis of the radial carpal and third carpal bones, joint capsule edema and capsular fibrosis, using a scale from 0 to 10, where 0 represented normal and 10 represented severe pathology (60, 61). Scoring was based on involvement within the intercarpal joint only. Final scores for each pathology represent means of the 3 evaluators. Total MR pathology scores were determined from the sum of the individual pathologies (60, 61).
- the osteochondral fragment and synovial tissue removed during the endpoint arthroscopy were fixed in paraformaldehyde, decalcified and paraffin-embedded.
- Serial sections of 5 ⁇ m were mounted on charged slides, deparaffinized and rehydrated, and blocked in 3% peroxide/methanol for 10 minutes at room temperature. Alternate sections in regions of interest were stained with hematoxylin and eosin (H&E) and toluidine blue, respectively.
- H&E hematoxylin and eosin
- the section series were analyzed and graded by two blinded evaluators using a grading system adapted from McIlwraith et al. (63).
- articular cartilage integrity was scored based on signs of chondrocyte necrosis, cluster formation, fibrillation, and/or focal cell loss.
- the synovial membrane was evaluated and graded based on signs of vascularity, intimal hyperplasia, subintimal edema and/or subintimal fibrosis.
- Leukocytic infiltration was scored on the same scale as a readout of inflammation.
- the subchondral bone and repair interface was evaluated for matrix quality, osteochondral lesions, bone remodeling, and osteochondral splitting. The total score was calculated from the sum of the individual scores.
- Synovial fluid was digested with hyaluronidase as described for ELISA, and blood serum was incubated at 56° C. for 30 minutes for complement inactivation.
- serumless media a series of two-fold serial dilutions were generated from the pre-treated serum or synovial fluid.
- the diluted samples were mixed with ⁇ 1 ⁇ 10 9 vg scAAV.eqIL-1Ra packaged in AAV2.5 capsid in a total volume of 250 ⁇ l, and incubated for 1 hour at 37° C. to allow antibody binding.
- the mixtures were then added to confluent cultures of equine synovial fibroblasts in 24-well plates containing 250 ⁇ l culture medium (500 ⁇ l/well total volume). After incubation for 48 hours under standard culture conditions, the conditioned media were harvested and assayed for eqIL-1Ra content by ELISA. NAb titers were indicated as the inverse of highest dilution capable of reducing by 50% the eqIL-1Ra levels produced by cells infected with AAV.eqIL-1Ra pre-incubated as above, but without biological fluids.
- Analyses consisted of independent sample t tests, analysis of covariance t tests with baseline scores serving as covariates, and correlational analyses. In most cases one-tailed tests were employed since, a priori, it was hypothesized that the horses receiving treatment with scAAV.eqIL-1Ra would have lower mean values from the diagnostic assessments employed, thus dictating the direction of the tail.
- the horses in the Control group received a similar injection volume of saline.
- One week later (allowing time for onset of transgenic IL-1Ra expression), the horses were placed on an athletic training schedule for 10 weeks, which in the context of the osteochondral injury induces pathologies consistent with early stage OA.
- the intercarpal joints of the animals were evaluated arthroscopically, and the osteochondral fragment and adjacent synovium were collected for analysis. The lesion was debrided and repaired, and following recovery, the animals were returned to the research herd.
- ELISA measurement of synovial fluids from the OCF joints of the Treated group showed a significant increase in eqIL-1Ra content, throughout the 12 week study. Reaching a mean level of 214 ng/ml at two weeks post-injection, eqIL-1Ra production was ⁇ 4-fold greater than measured in healthy joints receiving the same viral dose ( FIG. 5 B ). Over the course of the training protocol, eqIL-1Ra expression gradually dropped, and at week 12 measured ⁇ 59 ng/ml, close to that observed in normal joints. In synovial fluids from OCF joints of the Control group, as well as sham-operated joints of both groups, IL-1Ra remained at pre-treatment levels throughout, and did not exceed 1 ng/ml.
- eqIL-1Ra content in urine and peripheral blood serum at each time point was also measured.
- eqIL-1Ra in urine remained consistently low ( ⁇ 3 ng/ml) with no meaningful differences between Treated and Control groups ( FIG. 5 D ).
- mean eqIL-1Ra in the blood serum remained less than 4 ng/ml for 9 of the 10 horses in both groups ( FIG. 5 E ).
- one horse from each of the Treated and the Control groups showed blood serum eqIL-1Ra levels that exceeded 100 ng/ml without obvious cause ( FIG. 5 F ).
- NAb AAV2.5 neutralizing antibody
- Magnetic resonance (MR) images acquired at the same time points provided a clearer representation of the changes in joint pathology associated with each osteochondral injury, allowing comparison of pre-treatment and end-point scores over the 12 week interval for each individual (24). In all cases, the changes in the MR images were primarily found medially, in the vicinity of the surgically generated fracture ( FIG. 7 A ).
- both groups showed equivalent changes in the joint capsule, with similar loss of capsular edema and increased fibrotic thickening, which was attributed primarily to the arthroscopic procedure and fluid infusion and less to the osteochondral lesion.
- FIGS. 8 B- 8 C Histologic examination of the recovered fragments and adjacent synovial tissues showed significant differences in the quality of the repair bone at the boundary of OCF lesion.
- FIGS. 8 B- 8 C Consistent with the findings from arthroscopy and MRI, in the Treated group the bony tissue at the interface appeared more mature, with greater mineralization and formation of lamellar bone with defined osteons ( FIG. 8 D ).
- the present data in the equine joint show that the pathologic status of the joint at the time of treatment has a potent, direct influence on transgenic expression.
- AAV.IL-1Ra delivery into inflamed joints with an acute osteochondral injury resulted in a ⁇ 5-fold increase in mean IL-1Ra levels over that seen in healthy joints.
- IL-1Ra in synovial fluid ranged more than 100-fold among the OCF joints at two weeks post treatment, in 9 out of 10 animals there was a strong direct correlation between the level of pathology (total MRI score) at the time of injection and downstream IL-1Ra production.
- the heightened IL-1Ra expression likewise gradually diminished, and at the 12 week endpoint approached levels produced in normal joints.
- IL-1Ra as a Therapeutic Gene in OA
- the Treated group showed significantly improved repair of the osteochondral fracture relative to Control.
- This finding appears to conflict with the literature indicating vital roles for cyclooxygenase-2 and the prostaglandins in fracture repair (50, 51).
- These molecules though, primarily contribute to the acute inflammatory phase of bone healing, which begins to resolve around 7-14 days post-injury, giving way to repair processes of cellular differentiation and matrix synthesis (52). While acute inflammation is required to initiate the repair process, persistent inflammation can impede activation of the Wnt/ ⁇ -catenin pathway and osteoblast differentiation, which inhibits bone repair (53, 54).
- the reduced inflammatory signaling from IL-1Ra overexpression likely served to enhance osteoblast differentiation during the repair phase leading to improved healing.
- treatment with AAV.IL-1Ra in a similar time frame post joint injury may provide therapeutic/prophylactic benefits in post-traumatic OA, combining reduced inflammation and enhanced tissue repair with potential downstream chondroprotection.
- IL-1Ra Intra-articular IL-1Ra expression over a wide range, no correlation between synovial fluid eqIL-1Ra content and therapeutic benefit was observed. This was attributed to the mode of action of IL-1Ra as a competitive inhibitor of the IL-1 type 1 receptor (4). Due to the potency of IL-1 signaling, IL-1Ra must be present in 100 to 1000 fold excess over IL-1 to completely inhibit its activity (55, 56). In the OCF joints, synovial fluid IL-1 was below the limit of detection (16 pg/ml). Thus, in the majority of treated joints, IL-1Ra was present in a 6,000-fold excess, and least 400-fold in the joints with the lowest expression.
- IL-1Ra has no known agonist effect (4), once available IL-1 receptors are occupied, additional IL-1Ra can provide no further benefit. Considering these points, then consistent ⁇ 24-25% improvement in joint pathology observed in the Treated group likely reflects the maximum benefit achievable in this disease model with this method of IL-1Ra delivery.
- IL-1Ra is well-suited to intra-articular gene therapies for OA. It does not require sophisticated regulation, only synthesis levels above the therapeutic threshold. Once achieved, overproduction has little apparent adverse consequence, and thus, it is tolerant of the wide variation associated with viral-mediated gene delivery in vivo.
- the data indicate that IL-1Ra gene delivery is unlikely to be a cure for OA, as it is only capable of blocking the IL-1 signaling component of an extremely complex disease involving large-scale pathologies and processes mediated at the level of the tissues and organism.
- IL-1 is a primary driver of the inflammatory cascade and plays an active role in the majority of erosive processes in OA, which are mediated at the cellular level, it has the potential to provide meaningful benefit to patients over a broad spectrum of disease severity.
- AAV.IL-1Ra combines efficacy with an appropriate level of safety, providing a profile supportive of clinical testing in human and equine OA.
- IL-1Ra human interleukin-1 receptor antagonist
- FIG. 10 shows the mean levels from three transfections with each plasmid construct. As expected, no measurable IL-1Ra was seen in the cultures receiving the scAAV.GFP plasmid. IL-1Ra expression from the 3 codon-modified cDNAs exceeded that from the native sequence by ⁇ 2-4 fold. While IL-1Ra expression from both constructs synthesized by GeneArt exceeded that from GeneScript, the GeneArt cDNA with the consensus Kozak sequence provided the highest IL-1Ra expression.
- FIG. 10 To confirm the results observed in 293 cells ( FIG. 10 ) in a different cell line, equal amounts of the scAAV vector plasmids containing the GeneArt codon modified human IL-1Ra cDNAs (with and without the Kozak leader sequence), were transfected into cultures of human osteosarcoma (OS) cells at ⁇ 75% confluency. Parallel cultures of OS cells were transfected with scAAV vector plasmids containing the coding sequences for GFP or native human IL-1Ra. Approximately 48 hours later, the media from the cultures was harvested and the IL-1Ra content was measured by commercially available ELISA. FIG. 11 shows the mean levels from three transfections with each plasmid. Similar to that seen in the 293 cells ( FIG. 10 ), human IL-1Ra expression from the OS cells receiving the modified constructs was substantially higher than that from the native human sequence, with the modified sequence with a Kozak sequence producing the highest levels overall.
- the scAAV vector plasmids containing the coding sequences for a) GFP, b) the native human IL-1Ra, and c) the GeneArt codon-modified human IL-1Ra sequence with Kozak leader (opt+K) were packaged into the AAV2 capsid.
- the titers of the respective viral preparations were determined by both PCR and slot blot assays. Cultures of primary human synovial fibroblasts were infected with both IL-1Ra viral preparations over a range of doses from 10 3 to 10 5 DNAse resistant viral genomes (vg) per cell.
- FIG. 13 shows the alignment of the native human IL-1Ra cDNA and the codon modified IL-1Ra sequence including the underlined Kozak sequence. The alignment shows that 105 of the 534 nucleotides in the native IL-1Ra cDNA sequence were changed in the modification. While the DNA sequence has been altered to improve translation and expression of the IL-1Ra RNA, the amino acid sequence of the translated protein is identical to the native protein.
- inventive embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed.
- inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein.
- a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
- the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
- This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified.
- “at least one of A and B” can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
(SEQ ID NO: 1) |
ATGGAAATCCGCAGGCGTTCTGTCAGACACCTAATCTCTCTCCTCCTTTT |
CTTGTTCTACTCAGAGACAGCCTGCCACCCTTTGGGGAAGAGACCCTGCA |
AGATGCAAGCCTTCAGAATCTGGGATGTTAACCAGAAGACCTTCTACATG |
AGGAATAACCAACTAGTTGCTGGATACTTGCAAGAATCAAATACTAAATT |
ACAAGAGAAGATAGATGTGGTGCCCATTGAGCCTGATGCTCTATTCCTGG |
GACTCCATGGGAGGAAGCTGTGCCTGGCCTGTGTCAAGTCTGGTGATGAG |
ATTAGGTTCCAATTGGAGGCAGTTAACATCACTGACCTGAGCAAGAACAA |
GGAGGAGAACAAGCGCTTCACCTTCATCCGCTCAAACAGTGGCCCCACCA |
CCAGCTTCGAGTCTGCCGCCTGCCCTGGCTGGTTCCTCTGCACGGCGCAG |
GAGGCAGACCGGCCCGTCAGCCTCACCAACAAGCCCAAAGAGTCCTTCAT |
GGTCACCAAGTTCTACCTCCAGGAGGACCAGTAG |
Example of Nucleotide Sequence of Codon-Modified eqIL-1Ra Encoding Gene:
(SEQ ID NO: 2) |
ATGGAAATCAGGCGCAGAAGCGTGCGCCACCTGATCAGCCTGCTGCTGTT |
CCTGTTCTACAGCGAGACAGCCTGCCACCCCCTGGGCAAGAGGCCCTGCA |
AGATGCAGGCCTTCAGGATCTGGGACGTGAACCAGAAAACCTTCTACATG |
CGCAACAACCAGCTGGTGGCCGGATACCTGCAGGAAAGCAACACCAAGCT |
GCAGGAAAAGATCGACGTCGTCCCCATCGACCCGACGCCCTGTTCCTGGG |
CCTGCACGGCAGAAAGCTGTGCCTGGCCTGCGTGAAGTCCGGCGACGAGA |
TCAGGTTTCAGCTGGAAGCCGTGAACATCACCGACCTGAGCAAGAACAAA |
GAGGAAAACAAGCGCTTCACCTTCATCAGAAGCAACAGCGGCCCCACCAC |
CAGCTTCGAGAGCGCCGCTTGCCCCGGCTGGTTCCTGTGTACAGCCCAGG |
AAGCCGACAGGCCCGTCAGCCTGACCAACAAGCCCAAAGAAAGCTTCATG |
GTCACCAAGTTCTATCTGCAAGAAGATCAGTAA |
(SEQ ID NO: 3) |
GCCACCATGGAAATCAGGCGCAGAAGCGTGCGCCACCTGATCAGCCTGCT |
GCTGTTCCTGTTCTACAGCGAGACAGCCTGCCACCCCCTGGGCAAGAGGC |
CCTGCAAGATGCAGGCCTTCAGGATCTGGGACGTGAACCAGAAAACCTTC |
TACATGCGCAACAACCAGCTGGTGGCCGGATACCTGCAGGAAAGCAACAC |
CAAGCTGCAGGAAAAGATCGACGTCGTCCCCATCGACCCGACGCCCTGTT |
CCTGGGCCTGCACGGCAGAAAGCTGTGCCTGGCCTGCGTGAAGTCCGGCG |
ACGAGATCAGGTTTCAGCTGGAAGCCGTGAACATCACCGACCTGAGCAAG |
AACAAAGAGGAAAACAAGCGCTTCACCTTCATCAGAAGCAACAGCGGCCC |
CACCACCAGCTTCGAGAGCGCCGCTTGCCCCGGCTGGTTCCTGTGTACAG |
CCCAGGAAGCCGACAGGCCCGTCAGCCTGACCAACAAGCCCAAAGAAAGC |
TTCATGGTCACCAAGTTCTATCTGCAAGAAGATCAGTAA |
(SEQ ID NO: 9) |
ATGGAAATCTGCAGAGGCCTCCGCAGTCACCTAATCACTCTCCTCCTCTT |
CCTGTTCCATTCAGAGACGATCTGCCGACCCTCTGGGAGAAAATCCAGCA |
AGATGCAAGCCTTCAGAATCTGGGATGTTAACCAGAAGACCTTCTATCTG |
AGGAACAACCAACTAGTTGCTGGATACTTGCAAGGACCAAATGTCAATTT |
AGAAGAAAAGATAGATGTGGTACCCATTGAGCCTCATGCTCTGTTCTTGG |
GAATCCATGGAGGGAAGATGTGCCTGTCCTGTGTCAAGTCTGGTGATGAG |
ACCAGACTCCAGCTGGAGGCAGTTAACATCACTGACCTGAGCGAGAACAG |
AAAGCAGGACAAGCGCTTCGCCTTCATCCGCTCAGACAGTGGCCCCACCA |
CCAGTTTTGAGTCTGCCGCCTGCCCCGGTTGGTTCCTCTGCACAGCGATG |
GAAGCTGACCAGCCCGTCAGCCTCACCAATATGCCTGACGAAGGCGTCAT |
GGTCACCAAATTCTACTTCCAGGAGGACGAGTAG |
Example of a Nucleotide Sequence of Codon-Modified Human IL-1Ra Encoding Gene:
(SEQ ID NO: 10) |
ATGGAAATCTGCAGAGGCCTGCGGAGCCACCTGATTACCCTGCTGCTGTT |
CCTGTTCCACAGCGAGACAATCTGCCGGCCCAGCGGCCGGAAGTCCAGCA |
AGATGCAGGCCTTCCGGATCTGGGACGTGAACCAGAAAACCTTCTACCTG |
CGGAACAACCAGCTGGTGGCCGGATACCTGCAGGGCCCCAACGTGAACCT |
GGAAGAGAAGATCGACGTGGTGCCCATCGAGCCCCACGCCCTGTTTCTGG |
GCATCCACGGCGGCAAGATGTGCCTGAGCTGCGTGAAGTCCGGCGACGAG |
ACAAGACTGCAGCTGGAAGCCGTGAACATCACCGACCTGAGCGAGAACCG |
GAAGCAGGACAAGAGATTCGCCTTCATCAGAAGCGACAGCGGCCCCACCA |
CCAGCTTTGAGAGCGCCGCCTGCCCCGGCTGGTTCCTGTGTACAGCCATG |
GAAGCCGACCAGCCCGTGTCCCTGACAAACATGCCCGACGAGGGCGTGAT |
GGTCACCAAGTTCTATTTTCAAGAAGATGAGTAA |
(SEQ ID NO: 11) |
GCCACCATGGAAATCTGCAGAGGCCTGCGGAGCCACCTGATTACCCTGCT |
GCTGTTCCTGTTCCACAGCGAGACAATCTGCCGGCCCAGCGGCCGGAAGT |
CCAGCAAGATGCAGGCCTTCCGGATCTGGGACGTGAACCAGAAAACCTTC |
TACCTGCGGAACAACCAGCTGGTGGCCGGATACCTGCAGGGCCCCAACGT |
GAACCTGGAAGAGAAGATCGACGTGGTGCCCATCGAGCCCCACGCCCTGT |
TTCTGGGCATCCACGGCGGCAAGATGTGCCTGAGCTGCGTGAAGTCCGGC |
GACGAGACAAGACTGCAGCTGGAAGCCGTGAACATCACCGACCTGAGCGA |
GAACCGGAAGCAGGACAAGAGATTCGCCTTCATCAGAAGCGACAGCGGCC |
CCACCACCAGCTTTGAGAGCGCCGCCTGCCCCGGCTGGTTCCTGTGTACA |
GCCATGGAAGCCGACCAGCCCGTGTCCCTGACAAACATGCCCGACGAGGG |
CGTGATGGTCACCAAGTTCTATTTTCAAGAAGATGAGTAA |
(SEQ ID NO: 4) |
TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCA |
ATATTGGCTATTGGCCATTGCATACGTTGTATCTATATCATAATATGTAC |
ATTTATATTGGCTCATGTCCAATATGACCGCCATGTTGGCATTGATTATT |
GACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCAT |
ATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGA |
CCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCAT |
AGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTAC |
GGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCG |
CCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCA |
GTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAG |
TCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGT |
GGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGT |
CAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTC |
GTAACAACTGCGATCGCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTG |
TACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATC |
TABLE 1 |
Distribution of AAV.GFP genomes following injection in the intercarpal joint of healthy horses and those |
with naturally-occurring OA. Values represent vector genome copies per microgram of genomic DNA and are |
means of at least three replicates ± SEM. Tissues and locations are in reference to the injected joint. |
Healthy | |
Tissue | Horse |
1 | |
|
|
|
|
||
Synovium | 178,313 ± 559 | 66,022 ± 167 | 16,460 ± 114 | 212,262 ± 237 | 15,590 ± 280 | 142,033 ± 720 | |
intercarpal joint | |||||||
Cartilage | 3,349 ± 43 | 989 ± 109 | 1,726 ± 59 | 2,499 ± 69 | 887 ± 19 | 6,177 ± 55 | |
intercarpal joint | |||||||
Antebrachiocarpal | 159 ± 86 | 202 ± 9 | ND | ND | ND | 84 ± 16 | |
synovium | |||||||
Peri-articular muscle | ND | ND | ND | ND | ND | ND | |
Contralateral | ND | ND | ND | ND | ND | ND | |
intercarpal synovium | |||||||
Contralateral | ND | ND | ND | ND | ND | ND | |
quadriceps | |||||||
Ipsilateral MCP | ND | ND | ND | ND | ND | ND | |
Brain | ND | ND | ND | ND | ND | ND | |
Heart | ND | ND | ND | ND | ND | ND | |
| ND | ND | 45 ± 5 | 380 ± 15 | ND | ND | |
Lung | ND | ND | ND | ND | ND | ND | |
Spleen | ND | ND | ND | 277 ± 64 | ND | ND | |
ND, not detected |
VS=√HDmax2+HDmin2 (22, 23)
- 1. R. F. Loeser, S. R. Goldring, C. R. Scanzello, M. B. Goldring, Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum 64, 1697-1707 (2012).
- 2. S. A. Olson, P. Home, B. Furman, J. Huebner, M. Al-Rashid, V. B. Kraus, F. Guilak, The role of cytokines in posttraumatic arthritis. J Am Acad Orthop Surg 22, 29-37 (2014).
- 3. M. Kapoor, J. Martel-Pelletier, D. Lajeunesse, J. P. Pelletier, H. Fahmi, Role of proinflammatory cytokines in the pathophysiology of osteoarthritis.
Nat Rev Rheumatol 7, 33-42 (2011). - 4. W. P. Arend, M. Malyak, C. J. Guthridge, C. Gabay, Interleukin-1 receptor antagonist: role in biology.
Annu Rev Immunol 16, 27-55 (1998). - 5. X. Chevalier, P. Goupille, A. D. Beaulieu, F. X. Burch, W. G. Bensen, T. Conrozier, D. Loeuille, A. J. Kivitz, D. Silver, B. E. Appleton, Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study.
Arthritis Rheum 61, 344-352 (2009). - 6. J. D. Kay, E. Gouze, T. J. Oligino, J. N. Gouze, R. S. Watson, P. P. Levings, M. L. Bush, A. Dacanay, D. M. Nickerson, P. D. Robbins, C. H. Evans, S. C. Ghivizzani, Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus.
J Gene Med 11, 605-614 (2009). - 7. R. S. Watson, T. A. Broome, P. P. Levings, B. L. Rice, J. D. Kay, A. D. Smith, E. Gouze, J. N. Gouze, E. A. Dacanay, W. W. Hauswirth, D. M. Nickerson, M. J. Dark, P. T. Colahan, S. C. Ghivizzani, scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints.
Gene Ther 20, 670-677 (2013). - 8. C. H. Evans, S. C. Ghivizzani, P. D. Robbins, Arthritis gene therapy and its tortuous path into the clinic. Transl Res 161, 205-216 (2013).
- 9. H. Madry, M. Cucchiarini, Advances and challenges in gene-based approaches for osteoarthritis.
J Gene Med 15, 343-355 (2013). - 10. K. R. Vincent, B. P. Conrad, B. J. Fregly, H. K. Vincent, The pathophysiology of osteoarthritis: a mechanical perspective on the knee joint.
PMR 4, S3-9 (2012). - 11. L. R. Goodrich, A. J. Nixon, Medical treatment of osteoarthritis in the horse—a review. Vet J 171, 51-69 (2006).
- 12. D. M. McCarty, P. E. Monahan, R. J. Samulski, Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis.
Gene Ther 8, 1248-1254 (2001). - 13. D. M. McCarty, H. Fu, P. E. Monahan, C. E. Toulson, P. Naik, R. J. Samulski, Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo.
Gene Ther 10, 2112-2118 (2003). - 14. D. D. Frisbie, S. C. Ghivizzani, P. D. Robbins, C. H. Evans, C. W. Mcllwraith, Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene.
Gene Ther 9, 12-20 (2002). - 15. E. Gouze, J. N. Gouze, G. D. Palmer, C. Pilapil, C. H. Evans, S. C. Ghivizzani, Transgene persistence and cell turnover in the diarthrodial joint: implications for gene therapy of chronic joint diseases.
Mol Ther 15, 1114-1120 (2007). - 16. S. Fath, A. P. Bauer, M. Liss, A. Spriestersbach, B. Maertens, P. Hahn, C. Ludwig, F. Schafer, M. Graf, R. Wagner, Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One 6, e17596 (2011).
- 17. M. Kozak, Interpreting cDNA sequences: some insights from studies on translation.
Mamm Genome 7, 563-574 (1996). - 18. C. Li, N. Diprimio, D. E. Bowles, M. L. Hirsch, P. E. Monahan, A. Asokan, J. Rabinowitz, M. Agbandje-McKenna, R. J. Samulski, Single Amino Acid Modification of Adeno-Associated Virus Capsid Changes Transduction and Humoral Immune Profiles. J Virol, (2012).
- 19. D. E. Bowles, S. W. McPhee, C. Li, S. J. Gray, J. J. Samulski, A. S. Camp, J. Li, B. Wang, P. E. Monahan, J. E. Rabinowitz, J. C. Grieger, L. Govindasamy, M. Agbandje-McKenna, X. Xiao, R. J. Samulski,
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.Mol Ther 20, 443-455 (2012). - 20. L. J. Sandell, T. Aigner, Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis.
Arthritis Res 3, 107-113 (2001). - 21. A. Ishihara, J. S. Bartlett, A. L. Bertone, Inflammation and immune response of
intra-articular serotype 2 adeno-associated virus or adenovirus vectors in a large animal model. Arthritis 2012, 735472 (2012). - 22. K. G. Keegan, C. G. MacAllister, D. A. Wilson, C. A. Gedon, J. Kramer, Y. Yonezawa, H. Maki, P. F. Pai, Comparison of an inertial sensor system with a stationary force plate for evaluation of horses with bilateral forelimb lameness. Am J Vet Res 73, 368-374 (2012).
- 23. K. G. Keegan, D. A. Wilson, J. Kramer, S. K. Reed, Y. Yonezawa, H. Maki, P. F. Pai, M. A. Lopes, Comparison of a body-mounted inertial sensor system-based method with subjective evaluation for detection of lameness in horses. Am J Vet Res 74, 17-24 (2013).
- 24. M. D. Winter, The basics of musculoskeletal magnetic resonance imaging: terminology, imaging sequences, image planes, and descriptions of basic pathologic change. Vet Clin North Am Equine Pract 28, 599-616 (2012).
- 25. L. R. Goodrich, J. N. Phillips, C. W. Mcllwraith, S. B. Foti, J. C. Grieger, S. J. Gray, R. J. Samulski, Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis. Mol
Ther Nucleic Acids 2, e70 (2013). - 26. P. J. Mease, K. Hobbs, A. Chalmers, H. El-Gabalawy, A. Bookman, E. Keystone, D. E. Furst, P. Anklesaria, A. E. Heald, Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a
phase 1 dose-escalation safety and tolerability study. Ann Rheum Dis 68, 1247-1254 (2009). - 27. P. J. Mease, N. Wei, E. J. Fudman, A. J. Kivitz, J. Schechtman, R. G. Trapp, K. F. Hobbs, M. Greenwald, A. Hou, S. A. Bookbinder, G. E. Graham, C. W. Wiesenhutter, L. Willis, E. M. Ruderman, J. Z. Forstot, M. J. Maricic, K. H. Dao, C. H. Pritchard, D. N. Fiske, F. X. Burch, H. M. Prupas, P. Anklesaria, A. E. Heald, Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a
phase 1/2 Study. J Rheumatol 37, 692-703 (2010). - 28. C. R. Scanzello, S. R. Goldring, The role of synovitis in osteoarthritis pathogenesis. Bone 51, 249-257 (2012).
- 29. R. Rollin, F. Marco, J. A. Jover, J. A. Garcia-Asenjo, L. Rodriguez, L. Lopez-Duran, B. Fernandez-Gutierrez, Early lymphocyte activation in the synovial microenvironment in patients with osteoarthritis: comparison with rheumatoid arthritis patients and healthy controls. Rheumatol Int 28, 757-764 (2008).
- 30. E. V. Schmidt, G. Christoph, R. Zeller, P. Leder, The cytomegalovirus enhancer: a pan-active control element in transgenic mice.
Mol Cell Biol 10, 4406-4411 (1990). - 31. R. Lane Smith, M. C. Trindade, T. Ikenoue, M. Mohtai, P. Das, D. R. Carter, S. B. Goodman, D. J. Schurman, Effects of shear stress on articular chondrocyte metabolism. Biorheology 37, 95-107 (2000).
- 32. F. Berenbaum, Signaling transduction: target in osteoarthritis.
Curr Opin Rheumatol 16, 616-622 (2004). - 33. C. J. Malemud, Protein kinases in chondrocyte signaling and osteoarthritis. Clin Orthop Relat Res, S145-151 (2004).
- 34. S. Rigoglou, A. G. Papavassiliou, The NF-κB signalling pathway in osteoarthritis. Int J
Biochem Cell Biol 45, 2580-2584 (2013). - 35. M. B. Goldring, K. B. Marcu, Cartilage homeostasis in health and rheumatic diseases.
Arthritis Res Ther 11, 224 (2009). - 36. M. B. Goldring, Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in health and osteoarthritis. Ther
Adv Musculoskelet Dis 4, 269-285 (2012). - 37. R. Liu-Bryan, R. Terkeltaub, Emerging regulators of the inflammatory process in osteoarthritis.
Nat Rev Rheumatol 11, 35-44 (2015). - 38. P. Loser, G. S. Jennings, M. Strauss, V. Sandig, Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 72, 180-190 (1998).
- 39. R. A. Johnson, S. M. Huong, E. S. Huang, Activation of the mitogen-activated protein kinase p38 by human cytomegalovirus infection through two distinct pathways: a novel mechanism for activation of p38. J Virol 74, 1158-1167 (2000).
- 40. R. U. Svensson, J. M. Barnes, O. W. Rokhlin, M. B. Cohen, M. D. Henry, Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res 67, 10445-10454 (2007).
- 41. J. L. Meier, M. J. Keller, J. J. McCoy, Requirement of multiple cis-acting elements in the human cytomegalovirus major immediate-early distal enhancer for viral gene expression and replication. J Virol 76, 313-326 (2002).
- 42. X. F. Liu, X. Wang, S. Yan, Z. Zhang, M. Abecassis, M. Hummel, Epigenetic control of cytomegalovirus latency and reactivation.
Viruses 5, 1325-1345 (2013). - 43. W. Bruening, B. Giasson, W. Mushynski, H. D. Durham, Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. Nucleic Acids Res 26, 486-489 (1998).
- 44. M. Ramanathan, G. Haskó, S. J. Leibovich, Analysis of signal transduction pathways in macrophages using expression vectors with CMV promoters: a cautionary tale. Inflammation 29, 94-102 (2005).
- 45. A. J. Simpson, G. A. Cunningham, D. J. Porteous, C. Haslett, J. M. Sallenave, Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide.
Hum Gene Ther 12, 1395-1406 (2001). - 46. A. V. Miagkov, A. W. Varley, R. S. Munford, S. S. Makarov, Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints. J Clin Invest 109, 1223-1229 (2002).
- 47. M. Khoury, J. Adriaansen, M. J. Vervoordeldonk, D. Gould, Y. Chernajovsky, P. Bigey, C. Bloquel, D. Scherman, P. P. Tak, C. Jorgensen, F. Apparailly, Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of
serotype 5 adeno-associated virus reduces arthritis.J Gene Med 9, 596-604 (2007). - 48. F. A. van de Loo, A. S. de Hooge, R. L. Smeets, A. C. Bakker, M. B. Bennink, 0. J. Arntz, L. A. Joosten, H. M. van Beuningen, P. K. van der Kraan, A. W. Varley, W. B. van den Berg, An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint.
Gene Ther 11, 581-590 (2004). - 49. K. A. Elsaid, L. Zhang, Z. Shaman, C. Patel, T. A. Schmidt, G. D. Jay, The impact of early intra-articular administration of interleukin-1 receptor antagonist on lubricin metabolism and cartilage degeneration in an anterior cruciate ligament transection model. Osteoarthritis Cartilage 23, 114-121 (2015).
- 50. X. Zhang, E. M. Schwarz, D. A. Young, J. E. Puzas, R. N. Rosier, R. J. O'Keefe, Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109, 1405-1415 (2002).
- 51. P. Geusens, P. J. Emans, J. J. de Jong, J. van den Bergh, NSAIDs and fracture healing.
Curr Opin Rheumatol 25, 524-531 (2013). - 52. L. Claes, S. Recknagel, A. Ignatius, Fracture healing under healthy and inflammatory conditions.
Nat Rev Rheumatol 8, 133-143 (2012). - 53. M. M. Matzelle, M. A. Gallant, K. W. Condon, N. C. Walsh, C. A. Manning, G. S. Stein, J. B. Lian, D. B. Burr, E. M. Gravallese, Resolution of inflammation induces osteoblast function and regulates the Wnt signaling pathway. Arthritis Rheum 64, 1540-1550 (2012).
- 54. J. Chang, F. Liu, M. Lee, B. Wu, K. Ting, J. N. Zara, C. Soo, K. Al Hezaimi, W. Zou, X. Chen, D. J. Mooney, C. Y. Wang, NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc Natl Acad Sci USA 110, 9469-9474 (2013).
- 55. W. P. Arend, H. G. Welgus, R. C. Thompson, S. P. Eisenberg, Biological properties of recombinant human monocyte-derived
interleukin 1 receptor antagonist. J Clin Invest 85, 1694-1697 (1990). - 56. W. P. Arend, The balance between IL-1 and IL-1Ra in disease. Cytokine
Growth Factor Rev 13, 323-340 (2002). - 57. R. D. Howard, C. W. McIlwraith, G. W. Trotter, J. K. Nyborg, Cloning of
equine interleukin 1 receptor antagonist and determination of its full-length cDNA sequence. Am J Vet Res 59, 712-716 (1998). - 58. H. Kato, T. Ohashi, H. Matsushiro, T. Watari, R. Goitsuka, H. Tsujimoto, A. Hasegawa, Molecular cloning and functional expression of equine interleukin-1 receptor antagonist. Vet Immunol Immunopathol 56, 221-231 (1997).
- 59. M. K. Boyce, T. N. Trumble, C. S. Carlson, D. M. Groschen, K. A. Merritt, M. P. Brown, Non-terminal animal model of post-traumatic osteoarthritis induced by acute joint injury. Osteoarthritis Cartilage 21, 746-755 (2013).
- 60. C. E. Kawcak, D. D. Frisbie, N. M. Werpy, R. D. Park, C. W. McIlwraith, Effects of exercise vs experimental osteoarthritis on imaging outcomes.
Osteoarthritis Cartilage 16, 1519-1525 (2008). - 61. D. D. Frisbie, C. E. Kawcak, C. W. McIlwraith, N. M. Werpy, Evaluation of polysulfated glycosaminoglycan or sodium hyaluronan administered intra-articularly for treatment of horses with experimentally induced osteoarthritis. Am
J Vet Res 70, 203-209 (2009). - 62. D. C. Dymock, M. P. Brown, K. A. Merritt, T. N. Trumble, Concentrations of stromal cell-derived factor-1 in serum, plasma, and synovial fluid of horses with osteochondral injury. Am J Vet Res 75, 722-730 (2014).
- 63. C. W. McIlwraith, D. D. Frisbie, C. E. Kawcak, C. J. Fuller, M. Hurtig, A. Cruz, The OARSI histopathology initiative—recommendations for histological assessments of osteoarthritis in the horse. Osteoarthritis Cartilage 18
Suppl 3, S93-105 (2010). - 64. C. Li, M. Hirsch, A. Asokan, B. Zeithaml, H. Ma, T. Kafri, R. J. Samulski, Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol 81, 7540-7547 (2007).
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/467,141 US11958886B2 (en) | 2016-12-07 | 2017-12-07 | IL-1RA cDNAs |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662431336P | 2016-12-07 | 2016-12-07 | |
US201762486944P | 2017-04-18 | 2017-04-18 | |
US16/467,141 US11958886B2 (en) | 2016-12-07 | 2017-12-07 | IL-1RA cDNAs |
PCT/US2017/065173 WO2018106956A2 (en) | 2016-12-07 | 2017-12-07 | IL-1RA CDNAs |
Publications (2)
Publication Number | Publication Date |
---|---|
US20200071371A1 US20200071371A1 (en) | 2020-03-05 |
US11958886B2 true US11958886B2 (en) | 2024-04-16 |
Family
ID=62491596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/467,141 Active 2039-12-17 US11958886B2 (en) | 2016-12-07 | 2017-12-07 | IL-1RA cDNAs |
Country Status (10)
Country | Link |
---|---|
US (1) | US11958886B2 (en) |
EP (1) | EP3551650A4 (en) |
JP (2) | JP7282378B2 (en) |
KR (1) | KR20190088561A (en) |
CN (1) | CN110225923A (en) |
AU (2) | AU2017371043B2 (en) |
BR (1) | BR112019011592A2 (en) |
CA (1) | CA3046347A1 (en) |
MX (1) | MX2019006614A (en) |
WO (1) | WO2018106956A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230130155A (en) | 2016-08-19 | 2023-09-11 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus |
BR112019011592A2 (en) | 2016-12-07 | 2019-10-22 | Univ Florida | il-1ra cdnas |
CN110938642B (en) * | 2018-09-25 | 2023-08-29 | 上海恒润达生生物科技股份有限公司 | Chimeric antigen receptor targeting CD123-BBz-IL1RN |
US20220016213A1 (en) * | 2018-11-28 | 2022-01-20 | Genascence Corporation | Methods and Compositions for Treating Osteoarthritis |
KR20220081971A (en) * | 2019-07-15 | 2022-06-16 | 메이라지티엑스 유케이 Ii 리미티드 | Modified AAV Capsid Protein for Treatment of Arthritic Diseases |
WO2024029331A1 (en) * | 2022-07-30 | 2024-02-08 | 国立大学法人 東京医科歯科大学 | Pharmaceutical composition for treating and/or preventing joint disease |
Citations (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995016353A1 (en) | 1993-12-14 | 1995-06-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Systemic gene treatment of connective tissue diseases |
US5747072A (en) | 1993-07-30 | 1998-05-05 | University Of Michigan | Adenoviral-mediated gene transfer to synovial cells in vivo |
US5756283A (en) | 1995-06-05 | 1998-05-26 | The Trustees Of The University Of Pennsylvania | Method for improved production of recombinant adeno-associated viruses for gene therapy |
US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
WO2001042304A1 (en) | 1999-12-10 | 2001-06-14 | Amgen, Inc. | Interleukin-1 receptor antagonist-related molecules and uses thereof |
WO2002038782A2 (en) | 2000-11-13 | 2002-05-16 | Arimedes Biotechnology Gmbh | Viral expression system |
US6429001B1 (en) | 2000-01-26 | 2002-08-06 | Chiron Corporation | Recombinant AAV packaging systems |
WO2002062375A1 (en) | 2001-02-06 | 2002-08-15 | Merck Patent Gmbh | Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
JP2002538770A (en) | 1998-11-10 | 2002-11-19 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | Viral vectors and methods for their production and administration |
US6482634B1 (en) | 1997-09-19 | 2002-11-19 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant AAV |
US6548286B1 (en) | 1997-04-14 | 2003-04-15 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
JP2003518371A (en) | 1999-12-10 | 2003-06-10 | アムジェン インコーポレイテッド | Interleukin-1 receptor antagonist-related molecules and uses thereof |
KR20030086429A (en) | 2002-05-01 | 2003-11-10 | 주식회사 제넥신 | Optimal Eukaryotic Expression Vector |
KR20030089291A (en) | 2002-05-17 | 2003-11-21 | 씨제이 주식회사 | Vector for dna vaccine having high expression effects and vaccine for hepatitis using the vector |
WO2004092211A1 (en) | 2003-04-17 | 2004-10-28 | Axaron Bioscience Ag | Non-fluorescent report protein activateable by proteolyse for fluorescence and the use thereof for detecting protease-depending events |
US20040237145A1 (en) | 1998-03-20 | 2004-11-25 | Graham Michael Wayne | Control of gene expression |
US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US20050271618A1 (en) | 2004-04-02 | 2005-12-08 | Andrei Raibekas | Methods of reducing aggregation of IL-1ra |
US20060014966A1 (en) | 2004-07-16 | 2006-01-19 | Wen-Cherng Lee | Cell adhesion inhibitors |
US7037492B2 (en) | 1990-12-20 | 2006-05-02 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
US20070009899A1 (en) | 2003-10-02 | 2007-01-11 | Mounts William M | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases |
US20070042462A1 (en) | 2005-08-21 | 2007-02-22 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
WO2007039699A2 (en) | 2005-09-30 | 2007-04-12 | Genethon | Proteinaceous substrate for the detection of calpain-3 activity |
US20070128177A1 (en) | 1999-05-28 | 2007-06-07 | Haim Burstein | Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
US20080166762A1 (en) | 2006-09-27 | 2008-07-10 | Reliance Life Science Pvt.Ltd. | HETEROLOGOUS PRODUCTION OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (IL-1Ra) IN PICHIA PASTORIS |
WO2008088895A2 (en) | 2007-01-18 | 2008-07-24 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma |
US20080187576A1 (en) | 2006-06-16 | 2008-08-07 | University Of Florida Research Foundation, Inc. | Methods for treating articular disease or dysfunction using self-complimentary adeno-associated viral vectors |
WO2008132485A2 (en) | 2007-05-01 | 2008-11-06 | Alligator Bioscience Ab | Mutants of interleukin- 1 receptor antagonist and uses thereof |
US7452696B2 (en) | 2006-10-27 | 2008-11-18 | National Taiwan University | Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo |
US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
US20090105148A1 (en) | 2006-03-23 | 2009-04-23 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Compositions and methods for treating myocardial infarction |
US20090104155A1 (en) | 2006-04-21 | 2009-04-23 | Goodrich Laurie R | Treatment of connective tissue disorders |
US7892809B2 (en) | 2004-12-15 | 2011-02-22 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
US20110076285A1 (en) | 2009-09-29 | 2011-03-31 | Ingeborg Stalmans | Methods and Compositions For Treatment of Ocular Fibrosis |
WO2012047093A1 (en) | 2010-10-05 | 2012-04-12 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of the sjögren's syndrome |
KR20120041139A (en) | 2010-10-20 | 2012-04-30 | 주식회사 한독약품 | Human interleukin-1 receptor antagonist-hybrid fc fusion protein |
US20120232130A1 (en) | 2009-04-16 | 2012-09-13 | Cepko Constance L | Methods for inhibiting starvation of a cell |
US20120237587A1 (en) | 2009-12-10 | 2012-09-20 | Orthogen Ag | Combination preparation including a corticosteroid and exosomes |
US20130021786A1 (en) | 2011-07-21 | 2013-01-24 | Noble Matthew D | Utility bag lighting |
US8529885B2 (en) | 2003-09-01 | 2013-09-10 | Academisch Medisch Centrum | AAV vectors for in vivo gene therapy of rheumatoid arthritis |
WO2013151672A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of oncology-related proteins and peptides |
US20130295614A1 (en) | 2012-05-02 | 2013-11-07 | Sangeetha Hareendran | Nucleotide sequences, methods, kit and a recombinant cell thereof |
CN103509100A (en) | 2012-06-15 | 2014-01-15 | 上海百迈博制药有限公司 | Interleukin-1acceptor antagonist mutant |
US8736207B2 (en) | 2011-01-03 | 2014-05-27 | General Electric Company | Method and system for power conversion |
US20140234255A1 (en) | 2012-11-26 | 2014-08-21 | The Curators Of The University Of Missouri | Microdystrophin peptides and methods for treating muscular dystrophy using the same |
WO2014170470A1 (en) | 2013-04-17 | 2014-10-23 | Universitätsklinikum Hamburg-Eppendorf | Gene-therapy vectors for treating cardiomyopathy |
CN104245941A (en) | 2012-02-02 | 2014-12-24 | 贝勒医学院 | Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis |
WO2015018860A1 (en) | 2013-08-09 | 2015-02-12 | Universitätsklinikum Hamburg-Eppendorf | New peptides having specificity for the lungs |
US20150050238A1 (en) | 2011-02-08 | 2015-02-19 | Abbvie Inc. | Treatment of osteoarthritis and pain |
WO2015031392A1 (en) | 2013-08-27 | 2015-03-05 | Research Institute At Nationwide Children's Hospital | Products and methods for treatment of amyotrophic lateral sclerosis |
WO2015044292A1 (en) | 2013-09-26 | 2015-04-02 | Universitat Autonoma De Barcelona | Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease |
US8999948B2 (en) | 2010-06-10 | 2015-04-07 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
US20150218586A1 (en) | 2013-10-15 | 2015-08-06 | Plasmidfactory Gmbh & Co. Kg | Minicircles with viral expression cassettes and their use in the transformation of cells for generating recombinant virus or viral gene vectors |
WO2015158749A2 (en) | 2014-04-17 | 2015-10-22 | Universitätsklinikum Hamburg-Eppendorf | Viral vector for the targeted transfer of genes in the brain and spinal cord |
WO2015168666A2 (en) | 2014-05-02 | 2015-11-05 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
US20150353938A1 (en) | 2014-04-15 | 2015-12-10 | Applied Genetic Technologies Corporation | Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) |
US20150361452A1 (en) | 2013-01-25 | 2015-12-17 | Baylor College Of Medicine | A Helper-Dependent Adenoviral Gene Therapy Delivery and Expression System |
US9216205B2 (en) | 2012-04-02 | 2015-12-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding granulysin |
US20160068844A1 (en) | 2013-04-17 | 2016-03-10 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
WO2018035451A1 (en) | 2016-08-19 | 2018-02-22 | Calimmune, Inc. | Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus |
WO2018035441A1 (en) | 2016-08-19 | 2018-02-22 | Colorado State University Research Foundation | Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus |
WO2018035457A1 (en) | 2016-08-19 | 2018-02-22 | Calimmune, Inc. | Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus |
WO2018106956A2 (en) | 2016-12-07 | 2018-06-14 | University Of Florida Research Foundation, Incorporated | IL-1RA CDNAs |
-
2017
- 2017-12-07 BR BR112019011592A patent/BR112019011592A2/en not_active Application Discontinuation
- 2017-12-07 WO PCT/US2017/065173 patent/WO2018106956A2/en unknown
- 2017-12-07 EP EP17878272.8A patent/EP3551650A4/en active Pending
- 2017-12-07 AU AU2017371043A patent/AU2017371043B2/en active Active
- 2017-12-07 US US16/467,141 patent/US11958886B2/en active Active
- 2017-12-07 CA CA3046347A patent/CA3046347A1/en active Pending
- 2017-12-07 CN CN201780082668.7A patent/CN110225923A/en active Pending
- 2017-12-07 MX MX2019006614A patent/MX2019006614A/en unknown
- 2017-12-07 KR KR1020197019529A patent/KR20190088561A/en not_active Application Discontinuation
- 2017-12-07 JP JP2019530450A patent/JP7282378B2/en active Active
-
2023
- 2023-03-13 AU AU2023201531A patent/AU2023201531A1/en active Pending
- 2023-03-24 JP JP2023047811A patent/JP2023078402A/en active Pending
Patent Citations (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7037492B2 (en) | 1990-12-20 | 2006-05-02 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
US5747072A (en) | 1993-07-30 | 1998-05-05 | University Of Michigan | Adenoviral-mediated gene transfer to synovial cells in vivo |
WO1995016353A1 (en) | 1993-12-14 | 1995-06-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Systemic gene treatment of connective tissue diseases |
US5756283A (en) | 1995-06-05 | 1998-05-26 | The Trustees Of The University Of Pennsylvania | Method for improved production of recombinant adeno-associated viruses for gene therapy |
US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US8809058B2 (en) | 1995-06-07 | 2014-08-19 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US7439065B2 (en) | 1995-06-07 | 2008-10-21 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US6951758B2 (en) | 1995-06-07 | 2005-10-04 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US7229823B2 (en) | 1997-04-14 | 2007-06-12 | Richard Jude Samulski | Methods for increasing the efficiency of recombinant AAV product |
US6548286B1 (en) | 1997-04-14 | 2003-04-15 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
US6482634B1 (en) | 1997-09-19 | 2002-11-19 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant AAV |
US20040237145A1 (en) | 1998-03-20 | 2004-11-25 | Graham Michael Wayne | Control of gene expression |
US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
JP2002538770A (en) | 1998-11-10 | 2002-11-19 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | Viral vectors and methods for their production and administration |
US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US20070128177A1 (en) | 1999-05-28 | 2007-06-07 | Haim Burstein | Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
JP2003518371A (en) | 1999-12-10 | 2003-06-10 | アムジェン インコーポレイテッド | Interleukin-1 receptor antagonist-related molecules and uses thereof |
WO2001042304A1 (en) | 1999-12-10 | 2001-06-14 | Amgen, Inc. | Interleukin-1 receptor antagonist-related molecules and uses thereof |
US6429001B1 (en) | 2000-01-26 | 2002-08-06 | Chiron Corporation | Recombinant AAV packaging systems |
US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
US7790154B2 (en) | 2000-06-01 | 2010-09-07 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
US8361457B2 (en) | 2000-06-01 | 2013-01-29 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
WO2002038782A2 (en) | 2000-11-13 | 2002-05-16 | Arimedes Biotechnology Gmbh | Viral expression system |
WO2002062375A1 (en) | 2001-02-06 | 2002-08-15 | Merck Patent Gmbh | Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
KR20030086429A (en) | 2002-05-01 | 2003-11-10 | 주식회사 제넥신 | Optimal Eukaryotic Expression Vector |
KR20030089291A (en) | 2002-05-17 | 2003-11-21 | 씨제이 주식회사 | Vector for dna vaccine having high expression effects and vaccine for hepatitis using the vector |
WO2004092211A1 (en) | 2003-04-17 | 2004-10-28 | Axaron Bioscience Ag | Non-fluorescent report protein activateable by proteolyse for fluorescence and the use thereof for detecting protease-depending events |
US8529885B2 (en) | 2003-09-01 | 2013-09-10 | Academisch Medisch Centrum | AAV vectors for in vivo gene therapy of rheumatoid arthritis |
US20070009899A1 (en) | 2003-10-02 | 2007-01-11 | Mounts William M | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases |
US20050271618A1 (en) | 2004-04-02 | 2005-12-08 | Andrei Raibekas | Methods of reducing aggregation of IL-1ra |
US20060014966A1 (en) | 2004-07-16 | 2006-01-19 | Wen-Cherng Lee | Cell adhesion inhibitors |
US7892809B2 (en) | 2004-12-15 | 2011-02-22 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
US20070042462A1 (en) | 2005-08-21 | 2007-02-22 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
WO2007039699A2 (en) | 2005-09-30 | 2007-04-12 | Genethon | Proteinaceous substrate for the detection of calpain-3 activity |
US20090105148A1 (en) | 2006-03-23 | 2009-04-23 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Compositions and methods for treating myocardial infarction |
US20090104155A1 (en) | 2006-04-21 | 2009-04-23 | Goodrich Laurie R | Treatment of connective tissue disorders |
US20080187576A1 (en) | 2006-06-16 | 2008-08-07 | University Of Florida Research Foundation, Inc. | Methods for treating articular disease or dysfunction using self-complimentary adeno-associated viral vectors |
US20080166762A1 (en) | 2006-09-27 | 2008-07-10 | Reliance Life Science Pvt.Ltd. | HETEROLOGOUS PRODUCTION OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (IL-1Ra) IN PICHIA PASTORIS |
US7452696B2 (en) | 2006-10-27 | 2008-11-18 | National Taiwan University | Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo |
WO2008088895A2 (en) | 2007-01-18 | 2008-07-24 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma |
US7892824B2 (en) | 2007-01-18 | 2011-02-22 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nNOS to the sarcolemma |
JP2010516252A (en) | 2007-01-18 | 2010-05-20 | ユニヴァーシティ オブ ミズーリー−コロンビア | Synthetic mini / micro-dystrophin gene that restores nNOS in the muscle sheath |
WO2008132485A2 (en) | 2007-05-01 | 2008-11-06 | Alligator Bioscience Ab | Mutants of interleukin- 1 receptor antagonist and uses thereof |
US20120232130A1 (en) | 2009-04-16 | 2012-09-13 | Cepko Constance L | Methods for inhibiting starvation of a cell |
US20110076285A1 (en) | 2009-09-29 | 2011-03-31 | Ingeborg Stalmans | Methods and Compositions For Treatment of Ocular Fibrosis |
US20120237587A1 (en) | 2009-12-10 | 2012-09-20 | Orthogen Ag | Combination preparation including a corticosteroid and exosomes |
US8999948B2 (en) | 2010-06-10 | 2015-04-07 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
WO2012047093A1 (en) | 2010-10-05 | 2012-04-12 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of the sjögren's syndrome |
KR20120041139A (en) | 2010-10-20 | 2012-04-30 | 주식회사 한독약품 | Human interleukin-1 receptor antagonist-hybrid fc fusion protein |
US20130217864A1 (en) | 2010-10-20 | 2013-08-22 | Handok Pharmaceuticals Co., Ltd. | Human interleukin-1 receptor antagonist - hybrid fc fusion protein |
US8736207B2 (en) | 2011-01-03 | 2014-05-27 | General Electric Company | Method and system for power conversion |
US20150050238A1 (en) | 2011-02-08 | 2015-02-19 | Abbvie Inc. | Treatment of osteoarthritis and pain |
US20130021786A1 (en) | 2011-07-21 | 2013-01-24 | Noble Matthew D | Utility bag lighting |
CN104245941A (en) | 2012-02-02 | 2014-12-24 | 贝勒医学院 | Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis |
US20150031083A1 (en) | 2012-02-02 | 2015-01-29 | Baylor College Of Medicine | Adenoviral-based biological delivery and expression system for use in the treatment of Osteoarthritis |
US20140141067A1 (en) | 2012-04-02 | 2014-05-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding septin-4 |
US20140107189A1 (en) | 2012-04-02 | 2014-04-17 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US9216205B2 (en) | 2012-04-02 | 2015-12-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding granulysin |
JP2015518816A (en) | 2012-04-02 | 2015-07-06 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | Modified polynucleotides for the production of oncology related proteins and peptides |
WO2013151672A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of oncology-related proteins and peptides |
US20130295614A1 (en) | 2012-05-02 | 2013-11-07 | Sangeetha Hareendran | Nucleotide sequences, methods, kit and a recombinant cell thereof |
CN103509100A (en) | 2012-06-15 | 2014-01-15 | 上海百迈博制药有限公司 | Interleukin-1acceptor antagonist mutant |
US20140234255A1 (en) | 2012-11-26 | 2014-08-21 | The Curators Of The University Of Missouri | Microdystrophin peptides and methods for treating muscular dystrophy using the same |
US20150361452A1 (en) | 2013-01-25 | 2015-12-17 | Baylor College Of Medicine | A Helper-Dependent Adenoviral Gene Therapy Delivery and Expression System |
WO2014170470A1 (en) | 2013-04-17 | 2014-10-23 | Universitätsklinikum Hamburg-Eppendorf | Gene-therapy vectors for treating cardiomyopathy |
US20160068844A1 (en) | 2013-04-17 | 2016-03-10 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
WO2015018860A1 (en) | 2013-08-09 | 2015-02-12 | Universitätsklinikum Hamburg-Eppendorf | New peptides having specificity for the lungs |
WO2015031392A1 (en) | 2013-08-27 | 2015-03-05 | Research Institute At Nationwide Children's Hospital | Products and methods for treatment of amyotrophic lateral sclerosis |
WO2015044292A1 (en) | 2013-09-26 | 2015-04-02 | Universitat Autonoma De Barcelona | Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease |
US20150218586A1 (en) | 2013-10-15 | 2015-08-06 | Plasmidfactory Gmbh & Co. Kg | Minicircles with viral expression cassettes and their use in the transformation of cells for generating recombinant virus or viral gene vectors |
US20150353938A1 (en) | 2014-04-15 | 2015-12-10 | Applied Genetic Technologies Corporation | Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) |
WO2015158749A2 (en) | 2014-04-17 | 2015-10-22 | Universitätsklinikum Hamburg-Eppendorf | Viral vector for the targeted transfer of genes in the brain and spinal cord |
WO2015168666A2 (en) | 2014-05-02 | 2015-11-05 | Genzyme Corporation | Aav vectors for retinal and cns gene therapy |
WO2018035451A1 (en) | 2016-08-19 | 2018-02-22 | Calimmune, Inc. | Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus |
WO2018035441A1 (en) | 2016-08-19 | 2018-02-22 | Colorado State University Research Foundation | Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus |
WO2018035457A1 (en) | 2016-08-19 | 2018-02-22 | Calimmune, Inc. | Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus |
CN109843306A (en) | 2016-08-19 | 2019-06-04 | 卡琳缪恩股份有限公司 | Use the method and composition of self-complementary type recombinant adeno-associated virus treatment illness |
US20190381140A1 (en) | 2016-08-19 | 2019-12-19 | University Of Florida Research Foundation, Incorporated | Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus |
US11207382B2 (en) | 2016-08-19 | 2021-12-28 | University Of Florida Research Foundation, Incorporated | Compositions for treating conditions using recombinant self-complementary adeno-associated virus |
US20220175887A1 (en) | 2016-08-19 | 2022-06-09 | University Of Florida Research Foundation, Incorporated | Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus |
WO2018106956A2 (en) | 2016-12-07 | 2018-06-14 | University Of Florida Research Foundation, Incorporated | IL-1RA CDNAs |
Non-Patent Citations (65)
Title |
---|
[No Author Listed] UniProt Accession No. O18999. Sep. 21, 2022. 7 pages. |
Alexaki et al., Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies. Sci Rep. Oct. 29, 2019;9(1):15449. doi: 10.1038/s41598-019-51984-2. |
Altschul et al., Basic local alignment search tool. J Mol Biol. Oct. 5, 1990; 215(3):403-10. |
Bowles et al., Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther. Feb. 2012;20(2):443-55. doi: 10.1038/mt.2011.237. Epub Nov. 8, 2011. |
Cao et al. Therapeutic targeting and rapid mobilization of endosteal HSC using a small molecule integrin antagonist. Nature Communications. 2016; 7:11007. |
Chang et al., The production and characterization of a modified recombinant interleukin-1 receptor antagonist. Immunol Invest. Jul. 1996;25(4):355-68. |
Chupradit et al., Validation of Promoters and Codon Optimization on CRISPR/Cas9-Engineered Jurkat Cells Stably Expressing αRep4E3 for Interfering with HIV-1 Replication. Int J Mol Sci. Nov. 30, 2022;23(23):15049. doi: 10.3390/ijms232315049. |
Corpet, Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. Nov. 25, 1988; 16(22):10881-90. |
Del Rey et al., Transcriptome analysis reveals specific changes in osteoarthritis synovial fibroblasts. Ann Rheum Dis. Feb. 2012;71(2):275-80. doi: 10.1136/annrheumdis-2011-200281. Epub Oct. 21, 2011. |
EP 17842207.7, Mar. 3, 2020, Extended European Search Report. |
EP 17878272.8, Jun. 9, 2020, Extended European Search Report. |
Evans et al., Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther. Jun. 20, 1996; 7(10):1261-80. |
Evans et al., Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A. Jun. 14, 2005; 102(24):8698-703. Epub Jun. 6, 2005. |
Extended European Search Report for Application No. EP 17842207.7 dated Mar. 3, 2020. |
Extended European Search Report for Application No. EP 17878272.8 dated Jun. 9, 2020. |
Fath et al., Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One. Mar. 3, 2011;6(3):e17596. doi: 10.1371/journal.pone.0017596. Erratum in: PLoS One. 2011;6(3). doi: 10.1371/annotation/039deb02-bbe7-406c-a876-341cc4f3fefa. |
Frisbie et al, Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Therapy (2002) 9, 12-20. * |
Frisbie et al., Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther. Jan. 2002; 9(1):12-20. |
Garmory et al., DNA vaccines: improving expression of antigens. Genet Vaccines Ther. Sep. 16, 2003;1(1):2. doi: 10.1186/1479-0556-1-2. |
Genbank: AY026462.1, Canis familiaris interleukin-1 receptor antagonist mRNA, complete cds. 68.71.72.74 GenBank. Feb. 12, 2001. pp. 1-12. Retrieved from the Internet: https://www.ncbi.nlm.nih.gov/nuccore/AY026462.1 on Oct. 14, 2017. |
Goodrich et al, Optimization of scAAVIL-1ra in Vitro and in Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis. Molecular Therapy-Nucleic Acids (2013) 2, e70. * |
Goodrich et al, Optimization of scAAVIL-1ra in Vitro and in Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis. Molecular Therapy-Nucleic Acids (2013) 2, e70. 10 pages. * |
Goodrich et al. Optimization of scAAVIL-1ra in Vitro and in Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis. Mol Ther Nucleic Acids. Feb. 5, 2013;2:e70. doi: 10.1038/mtna.2012.61. |
Goodrich et al., scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy. Gene Ther. Jul. 2015;22(7):536-45. doi: 10.1038/gt.2015.21. Epub Apr. 23, 2015. |
Goss et al., Safety, Tolerability and Pharmacokinetics of Abt-981, an IL-1A and IL-1β Dual Target Biologic Drug in Development for Osteoarthritis, following Single Dose Administration in Healthy Subjects. Annals of the Rheumatic Diseases 2014; 73:755-756. |
He et al., Lentivirus transduced interleukin-1 receptor antagonist gene expression in murine bone marrow-derived mesenchymal stem cells in vitro. Mol Med Rep. Sep. 2015;12(3):4063-4070. doi: 10.3892/mmr.2015.4003. Epub Jun. 26, 2015. |
Higgins et al., CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene. Dec. 15, 1988; 73(1):237-44. |
Higgins et al., Fast and sensitive multiple sequence alignments on a microcomputer. Comput Appl Biosci. Apr. 1989; 5(2):151-3. |
Huang et al., Parallelization of a local similarity algorithm. Parallelization of a local similarity algorithm. Comput Appl Biosci. Apr. 1992; 8(2):155-65. |
Husain et al., Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters. Gene Ther. Jul. 2009;16(7):927-32. doi: 10.1038/gt.2009.52. Epub May 21, 2009. |
International Preliminary Report on Patentability for Application No. PCT/US2017/047589 dated Feb. 19, 2019. |
International Preliminary Report on Patentability for Application No. PCT/US2017/065173 dated Jun. 11, 2019. |
International Search Report and Written Opinion for Application No. PCT/US2017/047589 dated Nov. 8, 2017. |
International Search Report and Written Opinion for Application No. PCT/US2017/065173 dated May 6, 2018. |
Kamath et al., Simultaneous Targeting of IL-lα and IL-1β by a Dual-Variable-Domain Immunoglobulin (DVD-IgTM) Prevents Cartilage Degradation in Preclinical Models of Osteoarthritis. Osteoarthritis and Cartilage. 2011; 19S1:S64. |
Kay et al., Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus. J Gene Med. Jul. 2009;11(7):605-14. |
Kay et al., Self-Complementary Vectors Significantly Enhance AAV-Mediated Gene Transfer to Joint Tissues. Mol Ther. Jan. 1, 2006;13:S420-1. |
Kent, BLAT—the BLAST-like alignment tool. Genome Res. Apr. 2002; 12(4):656-64. |
Klein et al., Functional testing of thousands of osteoarthritis-associated variants for regulatory activity. Nat Commun. Jun. 4, 2019;10(1):2434. doi: 10.1038/s41467-019-10439-y. |
Lacy et al., Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs. 2015; 7(3):605-19. doi: 10.1080/19420862.2015.1026501. |
Makarov et al., Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A. Jan. 9, 1996;93(1):402-6. doi: 10.1073/pnas.93.1.402. |
McCoy, Animal Models of Osteoarthritis: Comparisons and Key Considerations. Vet Pathol. Sep. 2015;52(5):803-18. doi: 10.1177/0300985815588611. Epub Jun. 10, 2015. |
McIlwraith et al., The horse as a model of naturally occurring osteoarthritis. Bone Joint Res. Nov. 1, 2012;1(11):297-309. doi: 10.1302/2046-3758.111.2000132. |
Needleman et al., A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol. Mar. 1970; 48(3):443-53. |
Pan et al., Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum. Feb. 2000;43(2):289-97. |
PCT/US2017/047589, Feb. 19, 2019, International Preliminary Report on Patentability. |
PCT/US2017/047589, Nov. 8, 2017, International Search Report and Written Opinion. |
PCT/US2017/065173, Jun. 11, 2019, International Preliminary Report on Patentability. |
PCT/US2017/065173, May 9, 2018, International Search Report and Written Opinion. |
Pearson et al., Improved tools for biological sequence comparison. Proc Natl Acad Sci U S A. Apr. 1988; 85(8):2444-8. |
Pepinsky et al., Comparative assessment of the ligand and metal ion binding properties of integrins alpha9beta1 and alpha4beta1. Biochemistry. Jun. 4, 2002; 41(22):7125-41. |
Smith et al., Comparison of biosequences. Adv. Appl. Math. Dec. 1981. 2:482-489. |
U.S. Appl. No. 16/326,488, filed Feb. 19, 2019, Bartlett. |
U.S. Appl. No. 17/555,320, filed Dec. 17, 2021, Bartlett et al. |
Van De Loo et al., An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint. Gene Ther. Apr. 2004; 11(7):581-90. |
Wang et al., Dual Variable Domain-Immunoglobulin (Dvd-Igâ,,¢) Abt-981 Simultaneously and Dose-Dependently Inhibits Interleukin-1 Î'lpha and -1 Î3 eta in Subjects with Knee Osteoarthritis. 2015 ACR/ARHP Annual Meeting Abstract No. 318. |
Wang et al., Interleukin-1 Dual Variable Domain Immunoglobulin, a new Potential Treatment for Osteoarthritis. Osteoarthritis and Cartilage. 2014; 22:S462-S463. |
Wang et al., Interleukin-1 Dual Variable-Domain Immunoglobulin Reduces Multiple Imflammatory Markers in Knee Osteoarthritis patients. Scientific Abstracts. 2014; SAT0448. |
Wang et al., Interleukin-1 Dual-Variable Domain Immunoglobulin Reduces Multiple Inflammatory Markers in Knee Osteoarthritis Patients. 2014 ACR/ARHP Annual Meeting Abstract No. 2237. |
Wang et al., Phase 1 Studies of Anti-Interleukin-1 Dual-Variable Domain Immunoglobulin in Healthy Subjects and Patients with Osteoarthritis. Osteoarthritis and Cartilage. 2015; 23:A398-399. |
Wang et al., Safety and biodistribution assessment of sc-rAAV2.5IL-1Ra administered via intra-articular injection in a mono-iodoacetate-induced osteoarthritis rat model. Mol Ther Methods Clin Dev. Jan. 13, 2016; 3:15052. doi: 10.1038/mtm.2015.52. eCollection 2016. |
Watson et al, Exploring the capacity of local self-complimentary aav mediated delivery of equine IL-1Ra to block the symptoms and progression of osteoarthritis in an equine model. Molecular Therapy, (Jun. 2014) vol. 22, Supp. SUPPL. 1, pp. S292. Abstract No. 757. * |
Watson et al, ScAAV provides sustained expression of a homologous therapeutic transgene in large mammalian joints, with enhanced expression in osteoarthritis. Molecular Therapy, (Jun. 2013) vol. 21, Supp. SUPPL. 1, pp. S36. Abstract No. 88. * |
Watson et al., scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther. Jun. 2013; 20(6):670-7. doi: 10.1038/gt.2012.81. Epub Nov. 15, 2012. |
Wu et al., Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs. Jul.-Aug. 2009; 1(4):339-47. Epub Jul. 10, 2009. |
Also Published As
Publication number | Publication date |
---|---|
BR112019011592A2 (en) | 2019-10-22 |
CN110225923A (en) | 2019-09-10 |
MX2019006614A (en) | 2019-10-15 |
JP7282378B2 (en) | 2023-05-29 |
EP3551650A2 (en) | 2019-10-16 |
AU2017371043A1 (en) | 2019-07-11 |
AU2017371043B2 (en) | 2022-12-15 |
CA3046347A1 (en) | 2018-06-14 |
JP2019536465A (en) | 2019-12-19 |
US20200071371A1 (en) | 2020-03-05 |
KR20190088561A (en) | 2019-07-26 |
AU2023201531A1 (en) | 2023-04-13 |
JP2023078402A (en) | 2023-06-06 |
EP3551650A4 (en) | 2020-07-08 |
WO2018106956A2 (en) | 2018-06-14 |
WO2018106956A3 (en) | 2018-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11958886B2 (en) | IL-1RA cDNAs | |
Evans et al. | Possible orthopaedic applications of gene therapy. | |
Watson Levings et al. | Gene therapy for osteoarthritis: pharmacokinetics of intra-articular self-complementary adeno-associated virus interleukin-1 receptor antagonist delivery in an equine model | |
ES2835031T3 (en) | Recombinant AAV vectors expressing osteoprotective genes, including HAS2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals | |
Watson Levings et al. | Self-complementary adeno-associated virus–mediated interleukin-1 receptor antagonist gene delivery for the treatment of osteoarthritis: test of efficacy in an equine model | |
US7846428B2 (en) | Articular cartilage gene therapy with recombinant vector encoding BMP-7 | |
CN111433367A (en) | Methods and materials for NT-3 gene therapy | |
Ulrich-Vinther et al. | Adeno-associated vector mediated gene transfer of transforming growth factor-beta1 to normal and osteoarthritic human chondrocytes stimulates cartilage anabolism | |
JP2022517435A (en) | Treatment of diseases associated with deficiency of ENPP1 or ENPP3 | |
US20220211737A1 (en) | Compositions and methods for treatment of friedreichs ataxia | |
EA038300B1 (en) | IL-1Ra CDNAs | |
Levings et al. | Gene therapy for the treatment of equine osteoarthritis | |
US10293031B2 (en) | Compositions and methods for promoting the mineralization of biological tissue | |
Liu et al. | Effects of rAAV-Mediated Overexpression of sox9 and TGF-ß via Alginate Hydrogel-Guided Vector Delivery on the Chondroreparative Activities of Human Bone Marrow-Derived Mesenchymal Stromal Cells | |
Venkatesan et al. | Alginate hydrogel-guided rAAV-mediated FGF-2 and TGF-β delivery and overexpression stimulates the biological activities of human meniscal fibrochondrocytes for meniscus repair | |
Haughan et al. | Administration and detection of gene therapy in horses: A systematic review | |
US11992517B2 (en) | Compositions and methods for promoting the mineralization of biological tissue | |
US20230272433A1 (en) | Enhancing Utrophin Expression in Cell by Inducing Mutations Within Utrophin Regulatory Elements and Therapeutic Use Thereof | |
Gaddy et al. | Current status of gene therapy for rheumatoid arthritis | |
WO2021231443A1 (en) | Compositions useful in treatment of krabbe disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GHIVIZZANI, STEVEN C.;REEL/FRAME:049433/0141 Effective date: 20180607 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION RETURNED BACK TO PREEXAM |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |